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INTRODUCTION 
Acute leukemia is characterized by the extensive accumulation 
of a specific type of immature hematopoietic cells at the expen-
se of the normal production of mature functional blood cells. The 
cause of the leukemic transformation of the hematopoietic cells, 
leading to a maturation arrest, is unknown. 
The only available treatment is empirical and consists in the 
administration of different chemotherapeutical agents, according 
to various schemes in relation to cell morphology. When the im-
mature cells are sensitive to the administered cytostatic drugs, 
they are more or less completely eradicated and repopulation of 
the bone-marrow with normal cell lines can occur. 
Most cytostatics act only on proliferating cells in certain 
phases of the cell cycle, and are almost ineffective to resting 
cells. The results of chemotherapy depend therefore in part on 
the proliferation pattern of the leukemic cell population. Unfor-
tunately in full-blown leukemia only a small fraction of the leu-
kemic cells is proliferating and this is certainly one of the rea-
sons why therapy often fails. 
Available techniques to obtain information about the cell 
proliferation, such as autoradiography and micro-spectrophotome-
try, are laborious and time-consuming. 
Pulse cytophotometry is a new technical method, developed in 
recent years, which provides very rapid and quantitative informa-
tion about the proliferation pattern of a given cell population. 
In this thesis the observations with pulse cytophotometry of bone-
marrow cell proliferation in different forms of acute leukemia 
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before, during and after chemotherapy are reported. 
In chapter 4 on acute myeloblastic leukemia (A.M.L.) the im-
portance of the proliferative activity of the blastic cells is 
demonstrated by the fact that the chance to attain a complete re-
mission is closely correlated with the percentage of cells which 
are "in cycle". In chapter 5 on acute lymphoblastic leukemia 
(A.L.L.) the good results of remission induction in this type of 
leukemia are explained by the demonstrated selective activity of 
prednisone on lymphoblasts. The possibilities of pulse cytophoto-
metry for the research of cell kinetic effects of cytostatic 
agents are demonstrated in chapter 6, dealing with the effects of 
Adriamycin, Daunomycin, Vincristine and Cytosine-Arabinoside. 
The reported results are regarded as first contributions 
for the ultimate aim of this study: to investigate if rapid infor-
mation about the proliferation pattern of bone-marrow cells, be-
fore, during and after cytostatic therapy,can add to a rational 
selection of optimal drug- and treatment-schemes and in this way 
improve the results of therapy in acute leukemia. 
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Chapter 1 
CELL KINETICS IN ACUTE LEUKEMIA 
1.1. THE CELL-LIFE CYCLE 
Present knowledge about the cell proliferation and the kine-
tics of proliferating cells is based on the concept of the cell 
cycle, formulated by Howard and Pele in 1953. The cell cycle is 
defined as the interval between completion of mitosis in a cell 
and a completion of the subsequent mitosis in a daughter cell. Du-
ring the cell cycle the biochemical events occur in the manner of 
a fixed time schedule (reviewed by Baserga, 1968, 1971), in con-
sequence of which it is possible to characterize phases in the 
intermitotic life of a cell. 
The cell cycle is subdivided in four consecutive phases: 
1. G.-phase: the interval from completion of mitosis to the onset 
of DNA-synthesis. In this period ribonucleic acids and proteins, 
including special enzymes for the subsequent DNA-replication like 
thymidine-kinase and DNA-polymerase, are synthesized. (Baserga, 
1968). Cells in the G.-phase can be recognized by a diploid DNA-
content of the nucleus, referred to as 2n DNA, corresponding 
to the number of chromosomes. The absolute DNA-content of all 
normal Gj-phase cells in an individual appears to be the 
same (Müller et al., 1969; Vendrely,1971). With different 
-12 
techniques a value of approximately 7 χ 10 g DNA per cell is mea­
sured in human leucocytes and bone-marrow cells (Blackburn et al., 
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1973; Müller et al., 1973). 
2. S-phase: the period of chromosomal DNA-replication. DNA-synthe-
sis occurs only during the S-phase, so that cells in this phase 
are recognizable by the incorporation of labeled DNA-precursors. 
S-phase cells are characterized also by a DNA-content between 2n 
DNA (diploid) and 4n DNA (tetraploid), correlated to the duplica-
ting chromosomes (Vendrely, 1971). 
3. G-,-phase: the period from the end of DNA-synthesis to the be-
ginning of mitosis. The cells in this phase are tetraploid, con-
taining 4n DNA after the replication of the chromosomes. RNA- and 
proteinsynthesis for the subsequent cell division occur during 
this phase. 
4. M-phase: the mitosis. This phase is recognizable by its typical 
figures of chromosomal condensation and division during the sub-
stages: prophase, metaphase, anaphase and telophase. M-phase cells 
also have a tetraploid (4n) DNA-content. 
1.2. ANALYSIS OF CELL PROLIFERATION PATTERNS 
The proliferative activity of a cell population is mainly 
characterized by the fraction of cells in DNA-synthesis (S-phase) 
and mitosis (M-phase). Methods for the research of cell prolife-
ration-kinetics deal mostly with the measurement of these two 
phases of the cell cycle. 
The mitotic index (M.I.) 
The mitosis is a morphological marker of the cell cycle. The 
percentage of mitotic figures counted in a cell population is de-
fined as the mitotic index (M.I.). Several authors (reviewed by 
Killmann,1968) reported a mitotic index of 0.5 per cent in leuke-
mic blast cells and 1.0 per cent in normal myeloid precursors. 
The decrease of the mitotic index could be due to a shortening of 
the duration of mitosis in leukemic blast cells, but actually the 
mitotic duration in leukemic cells, estimated by time-lapse photo-
graphy, appeared to be 1 hour, against 0.6 hour in normal proli-
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ferating bone-marrow cells (Killmann, 1968; Rondanelli et al., 
1969) . 
The labeling index. 
The fraction of S-phase cells in a cell population is an im-
portant parameter of the proliferation since normally a cell whidi 
synthesizes DNA will go on to mitosis and cell division (Baserga, 
1968). The determination of the fraction of S-phase cells is most-
ly performed by autoradiography, a method based on the selective 
incorporation of radioactive labeled DNA precursors m DNA-synthe-
sizing cells. Especially tritium labeled thymidine (^ H-TDR) proved 
to be a reliable marker of the hematopoietic cells in the S-phase 
(Rubini et al., 1960; Killmann et al., 1963; Saunders et al., 
1967). Within one hour after the administration of H-TDR in vivo 
or in vitro the S-phase cells are labeled (flash labeling). The 
labeling of the cells is demonstrated by autoradiography in smears 
covered with a photographic emulsion (Rubini et al., 1960; Wimber, 
1963). 
The percentage of H-TDR-labeled cells, indicating the frac-
tion of S-phase cells in a cell population, is called: the labeling 
index. One of the main advantages of autoradiography is that cell 
morphology is preserved, so that the labeling index of the diffe-
rent cell types can be determined separately. 
Labeling indices of normal bone-marrow cells. 
Autoradiographic data of normal bone-marrow are rather scarce . 
Killmann (196 8) reviewed the literature concerning the normal gra-
nulocytic precursors. Only myeloblasts, promyelocytes and myelo-
cytes incorporate H-TDR, whereas metamyelocytes, bands and seg-
mented granulocytes constitute the non-dividing maturating pool 
of the normal bone-marrow. The labeling index of normal myelo-
blasts is approximately 50 per cent, but the values reported in 
the literature vary considerably, with a range of 40 to 70 per 
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cent (Killmann,1972; Greenberg et al., 1972). The labeling indi-
ces of metamyelocytes and myelocytes appeared to be respectively 
40 and 25 per cent. Thus the labeling index decreases with pro-
ceeding maturation of the normal myeloid precursors. The average 
labeling index of all dividing myeloid cells in the normal bone 
marrow is estimated at 33 per cent (Killmann, 1968;Klein and Len-
nartz, 1972). This value is in agreement with the observations of 
Müller (1969), who investigated normal bone-marrow cells by micro-
cytophotometry. 
Labeling indices of normal erythropoiesis are rarely reported. 
Incorporation of H-TDR occurs in pro-normoblasts, basophilic and 
polychromatic normoblasts. Orthochromatic normoblasts are not la-
beled after one hourcfexposure to H-TDR. Like in myelopoiesis the 
earlier stages of erythroid precursors are labeled more frequent-
ly. The average labeling index of all erythroid precursors is ap-
proximately 25-30 per cent (Stn^ckmans et al., 1966; Schmid et 
al., 1966; Müller, 1969; Clarkson et al., 1970). 
Normal lymphocytes in the bone-marrow do not incorporate H-
TDR, but data about proliferation-kinetics of normal lymphopoiesis 
lack almost completely (Clarkson et al.,1970). 
Labeling index of leukemic blast cells. 
Labeling indices of leukemic myeloblasts and lymphoblasts 
are substantially lower than those of normal dividing bone-marrow 
cells (Saunders et al., 1967; Killmann, 1968; Clarkson, 1969). An 
average of 10 per cent was reported with a wide range of 2 to 26 
per cent. Essential differences between labeling indices of myelo-
blasts and lymphoblasts are not observed. 
1.3. DURATION OF THE CELL CYCLE PHASES 
The percentages of the cells in the various phases of the cell 
14 
cycle correlate with the duration of these phases. The absolute 
time it takes a cell to pass through a particular phase, can 
be calculated from the percentage of cells in that phase and the 
duration of the whole cell cycle. The duration of the cell cycle, 
the time which elapses between two consecutive cell divisions, 
is called the generation time (Tg). 
Measurements of the generation time can be done by labeling of 
DNA with radioactive thymidine and subsequent repeated autoradio­
graphic studies. At cell division the radioactive material in 
each cell is halved. Estimation of the mean labeling intensity 
per cell (mean grain count) at different time-intervals gives 
information about the diminution of the radio active material by 
celldivisions in relation to time and by this about the average 
generation time of the cells under investigation (Cronkite,1969 ; 
Clarkson, 19 69). The average generation time of normal myelo­
blasts, promyelocytes and myelocytes is calculated at 40-50 hours 
(Killmann, 1968; Cronkite, 1969), and at 25-30 hours for normal 
myeloblasts alone (Greenberg et al., 1972). 
The average generation time of leukemic blast cells may be estima­
ted at 95 hours (Clarkson et al., 1970) but reported values vary 
considerably (reviewed by Killmann, 1972) . In spite of the variable 
observations, it is generally agreed that the average generation 
time of leukemic cells is much longer than that of normal myeloid 
precursors. 
The duration of the S- and G2-phases is usually determined by 
the method of labeled mitosis curves (Quastler and Sherman, 1959). 
When a cell population is exposed to a flash-labeling with H-TDR 
it takes some time before the first labeled mitosis appears. This 
time-lag is a reflection of the G2~Phase. After appearance of the 
first labeled mitosis, the mitotic figijres remain labeled for a 
time equalling the duration of DNA-synthesis (Tg). 
In normal proliferating bone-marrow Τ of myeloid and erythroid 
precursors is about 13 to 14 hours (Strijckmans et al., 1966). 
In leukemic blast cells Τ varies between 13 and 20 hours (Green-
berg et al., 1972; Killmann, 1972). 
The duration of the G2-phase in normal bone-marrow is approxima-
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tely 2 hours (Stri^ckmans et al., 1966; Killmann, 1972) m leuke-
mic cells it was found to be 1^ to 4 hours (Greenberg et al., 
1972) . 
From these figures it can be concluded that the increase m 
the generation time of leukemic cells is mainly due to a lengthe-
ning of the G - phase duration. 
1.4. "PROLIFERATING" AND "NON-PROLIFERATING" LEUKEMIC BLAST CELLS 
IN THE BONE-MARROW 
The decrease in the labeling index, the mitotic index, and 
the prolongation of the average generation time of leukemic 
blast cells indicate a lower proliferative activity in leukemia. 
However the proliferative activity of all blasts in a leukemic 
bone-marrow is not equally depressed. Killmann et al. (1962), 
Gavosto et al. (1964) and Mauer and Fisher (1966) noted a high 
labeling index of the larger blast cells, whereas small blasts 
3 
were seldom labeled one hour after the administration of H-TDR. 
According to these observations a leukemic cell population can 
be divided into a proliferative pool of large blast cells, of which 
the proliferative activity is almost equal to that of normal mye-
loblasts, and a larger (65-85 per cent) pool of non-proliferatmg 
small blast cells. These non-proliferating cells appeared to ori-
ginate from the proliferating large blasts, as a kind of daughter 
cells, which have lost proliferative activity, and therefore were 
called G0-cells (Gavosto et al., 1964). 
About the nature of these non-proliferating cells exists much con-
troversy in the literature. It became apparent that these cells 
are not permanently non-proliferative, but on suitable stimula-
tion can resume proliferation and actually function as stem cells 
for the proliferating pool (Saunders and Mauer, 1969; Stn^ckmans 
et al., 1970; Killmann, 1972). During continuous infusions of H-
TDR in acute leukemia patients, Clarkson et al. (1969,1970a) ob-
served a gradual increase of the labeling index of the small blast 
cells. After 8-10 days of infusion 88-93 per cent of all blast 
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cells were labeled, and after 20 days a labeling index of 92-99 per 
cent was found, indicating that most cells had passed DNA-synthe-
sis within this period. But the labeling-intensity (mean grain 
count) in the large cells was higher than in the small cells, pro-
bably as a result of more cell divisions of the large blasts with-
in the same period. 
According to these observations the leukemic bone-marrow is 
now regarded as a cell population with a very variable generation 
time, mainly due to variations of the G.-phase duration (Clarkson 
1969, 1970; Killmann,1972). The non-proliferating blast cells re-
present cells with a prolonged G.-phase, whereas the proliferating 
blasts are the cells with a relative shorter generation time. 
Whether cells in a prolonged G.-phase should be called G is still 
a question of semantics, but as long as a biochemical distinction 
between cells with short or long G -phases lacks, it seems appro-
piate to consider all these cells in G.-phase (Clarkson, 1969). 
Killmann proposed the neutral term "quiescent" or "resting" cells 
for the prolonged G.-phase cells. 
1.5. THE KINETICS OF THE LEUKEMIC BLAST CELLS IN THE PERIPHERAL 
BLOOD 
The labeling index of the leukemic blast cells in the peri-
pheral blood is generally much lower than in the bone-marrow. This 
discrepancy is probably due to a preferential release of the slow-
ly proliferating small blast cells from the bone-marrow into the 
blood, in analogy with the normal situation where only non-proli-
ferating mature cells are released into the blood. (Killmann,1968, 
1972) . 
The life-span of leukemic cells in the blood is limited to 33-36 
hours, and most blast cells do not reach mitosis in the blood. 
The fate of the leukemic cells in the marginal pool or in the 
tissues after leaving the blood is unknown. Probably most cells 
die, but sometimes proliferation of leukemic cells in extravascu-
lar sites occurs (Clarkson, 1969; Fliedner and Hoelzer, 1972; 
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Killmann, 1972) . 
1.6. THE KINETICS OF "NORMAL" BONE-MARROW CELLS IN ACUTE LEUKEMIA 
The very few observations on cell kinetics of the remaining 
morphological normal bone-marrow cells in acute leukemia indicate 
that the proliferation characteristics of these cells are almost 
normal (Mauer and Fisher, 1966; Clarkson, 1970b) . Hence, the re-
duced production of normal cells would be the result of an inhibi-
tion at the stem cell level. These observations are in favour of 
the clonal theory of the origin of acute leukemia, which supposes 
a clone of leukemic cells derived from one transformed stem cell, 
beside a suppressed population of normal stem cells (Clarkson, 
19 72). However some authors doubt this coexistence of a leukemic 
and a normal population, and regard all cells in the leukemic bone 
marrow, including the morphologically normal appearing cells, as 
leukemic or of leukemic origin (Killmann, 1972). Actually in a 
few patients an abnormal proliferation of the erythroid cells in 
the leukemic bone-marrow was found (reviewed by Killmann, 1972). 
1.7. CELL KINETICS AND CHEMOTHERAPY IN ACUTE LEUKEMIA 
Most currently used cytostatics for the treatment of acute 
leukemia are maximally effective on cells during one definite 
phase of the cell cycle.In general cells in S-, G_-and M-phase 
are much more sensitive to cytostatic treatment than the cells 
in the G.-phase or in extended G^phase i.e quiescent œlls(Lamp-
kin et al., 1972). It is obvious that the large fraction of res-
ting cells in acute leukemia forms a main obstacle for cytosta-
tic treatment. 
By means of continuous infusions with JH-TDR it has been 
shown that a small fraction of the leukemic cells remains in the 
non-vulnerable G.-phase for 20 days or even longer (Clarkson, 
1969) . The administration of cytostatic agents for such a long 
period, in order to kill all leukemic cells, v/ould also destroy 
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the normal stem cells so that a repopulation of the bone-marrow 
by normal cells becomes impossible. Therefore it was tried to ma-
nipulate leukemic cells in such a way that they would leave the 
extended G,-phase at a higher rate, and hence would become sensi-
tive to subsequent cytostatic treatment. This process, which is 
called cell- recruitment, was demonstrated after extra-corporeal 
irradiation of the blood (Chan and Hayhoe, 1971; Ernst et al., 
1971) and after injections of Cytosine-Arabinoside (Lampkin et al. 
, 1971, 1972) . 
A second way to achieve more effective therapy is to arrest the 
leukemic cells in a same cell cycle phase and to release them 
thereafter. This process is called ce11-synchronization. After 
synchronization cells proceed like a cohort in the cell cycle 
and can be killed more effectively by cytostatics during the pas-
sage of the drug-sensitive phases. 
Synchronization of leukemic cells was observed after injections of 
Vincristine (Klein and Lennartz, 1974) . Differences in such cell 
kinetic effects of therapy between the leukemic cells and the nor-
mal stem cells could be exploited for a selective killing of the 
leukemic cells. However the knowledge about cell kinetics of the 
normal stem cells is still very limited. 
With increasing knowledge about cell kinetic effects of dif-
ferent cytostatic agents on leukemic cells, a more optimal choice 
of combinations and timing of administration of different drugs 
(time-scheduling) is possible (Clarkson, 1971; Lampkin et al., 
1972; Klein and Lennartz, 1974). 
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Chapter 2 
PRINCIPLES OF PULSE CYTOPHOTOMETRY, 
AND THE APPLICATION IN DNA-MEASUREMENTS 
2.1. FLOW SYSTEM ANALYSIS 
A number of optical methods for the quantitative determina-
tion of various substances in single cells are known as cytophoto-
metry (Ruch, 1970). The measurement of fluorescent light, emitted 
by appropriately stained cells, proved to be a valuable method 
for the determination of cellular components, especially DNA-con-
tent (Böhm and Sprenger, 1968, 1973; Ruch, 1970). 
In micro-cytophotometry this fluorometric method is carried 
out on cells affixed to microscope slides (Böhm and Sprenger, 1968; 
Müller et al., 1972, 1974). In this system each single cell has 
to be focused in the fluorescence-microscope before measurement, 
a procedure rather time - consuming. To overcome this labo-
rious procedure flow-system analysis was developed, by which a 
suspension of fluorochromed cells is transported in a fluid stream 
through the focal plane of a microscope for fluorescence measure-
ments. Two types of instruments are available now for flow-system 
fluorometry: The Los Alamos Flow Microfluorometer, developed by 
Van Dilla et al. (1969) and the Pulse Cytophotometer, developed 
by Dittrich and Göhde(1969). After staining with different fluoro-
chromes the most important intracellular components, such as DNA, 
RNA, proteins, lipids and enzymes can be measured with these sys-
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terns. Practical applications are reported in differential leuco-
cyte counting (Adams and Kamentsky, 1971; Melamed et al., 1972, 
1973) fluorescent-antibody studies (Julius et al., 1972), histo-
compatibility testing (Drake et al., 1972), mixed-lymphocyte cul-
tures (Wagener et al., 1974),cancer-cell identification (Reif-
fenstuhl et al., 1971; Horan et al., 1974) and cell sorting (Stein-
kamp et al., 1974) . 
2.2. DNA-MEASUREMENTS BY FLOW SYSTEM FLUOROMETRY 
The most employed development in flow-system analysis has 
been fluorescent measurement of cellular DNA-contents. For quan-
titative measurement of DNA, the cell-nuclei have to be stained 
with a fluorescent dye that specifically and proportionally binds 
to cell-DNA. For this purpose a number of fluorescent dyes are 
available. Kasten (1959) recommended basic fluorochromes, of which 
acriflavine was found to be most suitable. 
Boshard (1964) described Auramine-o, which was used for flow mi-
cro-fluorometry by Trujillo and Van Dilla (1972) . Ruch (1964) 
experimented with diaminophenyl-oxadizole. Le Pecq and Paoletti 
(1967) introduced diamino-ethyl-phenyl-phenantridinium-bromide, 
better known as ethidium bromide. Recently Crissman and Stein-
kamp (1974), described very promising results with mithramycin 
as a specific DNA-stain. 
In this study DNA-measurements were taken after staining with 
ethidium bromide. Details of the staining method are described in 
chapter 3 . As in all fluorometric methods, the measurement of 
DNA by fluorescence of a bound dye reveals relative values. If 
absolute values are of interest, a comparison with standard cells 
of a known DNA-content is necessary. 
Measurement of the relative DNA-content of single cells in 
a cell population gives important information about the cell pro-
liferation. The DNA-content of cells is related to the different 
phases of the cell cycle (Vendrely, 1971). As described in chap-
ter 1 »cells in the G.-phase contain 2n DNA. The DNA-content of 
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S-phase cells is between 2n and 4n DNA. The G-- and M-phase cells 
with doubled chromosomes contain 4n DNA. Therefore the percentage 
of cells in G.-» S- and G2+fl-phase in a cell population can be 
determined by measuring the DNA-content of single cells. 
Flow micro-fluorometry and pulse cytophotometry were used 
for cell proliferation studies in a number of experimental cell 
systems (Crissman and Steinkamp, 1973; Crissman and Tobey, 1974; 
Göhde and Dittrich, 1971; Göhde, 1973; Kal, 1974; Laerum and Mau-
rer, 1973; Linden et al., 1973; Rajewsky, 1973; Schumann and Göh-
de, 1974; Smets, 1973; Tobey and Crissman, 1972; Tobey et al., 
1972) Pulse cytophotometry was first applied for proliferation stu-
dies in acute leukemia by Büchner et al. (1971, 1972, 1974). 
2.3. THE PULSE CYTOPHOTOMETER 
A commercially available pulse cytophotometer I.C.P.-11 (Phy-
we A.G., Göttingen, West-Germany) was used. In this instrument 
a suspension of the stained cells (denoted at 1 in the schematic 
figure 2.1) is sucked through a capillary. The exit of this ca-
pillary (2) with a diameter of 80ym adjusted in the focal plane 
of a fluorescence microscope (3), forms the measuring field. This 
field is homogeneously illuminated by incident excitation light 
with a high-pressure mercury-lamp (4). The wave-length of the ex-
citation light is adapted to a particular fluorochrome by proper 
choice of a combination of excitation filters. Every stained cell, 
passing the measuring field,emits a fluorescent light pulse. The 
height of each pulse is proportional to the amount of the dye present 
which reflects the quantity of the substance to be measured. The 
emission light-pulses are converted into electrical pulses by a 
photomultiplier (5), attached to the fluorescence microscope. The 
resulting electrical currents are amplified, analysed for ampli-
tude, and stored in the memory of a multichannel pulse-height ana-
lyser (8). The analyser delivers a frequency-distribution of fluo-
rescent light-emission per cell in a certain population. This re-
sult of a measurement is automatically recorded in a histogram (9). 
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Figure 2.1. 
SCHEME OF THE PULSE CYTOPHOTOMETER 
Л л Α Λ 
* 
Ni 
Schematic representation of the optical and electronical parts of 
the pulse cytophotometer. 
1: cell suspension, 2: measuring field, 3: fluorescence micros­
cope, 4: mercury lamp, 5: photomultiplier, 6: liquid reservoir, 
7: suction pump, 8: pulse height analyser, 9: histogram. 
The figures are explained in the text (2.3). 
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Dependent on the fluorochromed substance the recorded frequency-
distribution can be a DNA-histogram, protein-histogram, RNA-histo-
gram,etc. 
2.4. DNA-HISTOGRAM 
A DNA-histogram obtained with pulse cytophotometry of leuko-
cytes of normal blood is shown in figure 2.2 . Almost all cells 
contain approximately the same amount of DNA, according to the 2n 
DNA-content of non-proliferating cells. Figure 2.2 represents a 
histogram of the normal bone-marrow of the same person. Most of 
the bone-marrow cells are in the 2n-area, corresponding to cells 
in the G,-phase. Besides this G.-peak there is a smaller second 
peak of cells at the double DNA-value, corresponding to cells in 
G_- and M-phase. The cells between the two peaks, with a DNA-con-
tent between 2n and 4n, represent the cells in the S-phase. 
4 5 
The measuring time for 10 -10 fluorescent cells is about 5 minu-
tes . 
The DNA-content of normal diploid cells is found to be very 
constant (Vendrely, 1971; Kraemer et al., 1972). So, ideally the 
measured DNA-values of all G.-phase cells should be the same. Ac-
tually the G.-peak shows a variation of the measured values around 
the mean. In general a standard deviation of 4-6 per cent is found 
for the G.-peak. The standard deviation of the Gj+M-peak in histo-
grams with a distinct large peak at the 4n-value is equally small. 
This variation is partly due to instrumental deviations, espe-
cially of the photomultiplier (Göhde, 1973). Also variations in 
the staining of the cells with a fluorochrome can attribute to 
the dispersion of the measuring values. Nevertheless the standard 
deviations of pulse cytophotometric measurements are generally 
smaller than those of conventional cytophotometric methods (Krae-
mer et al., 1972; Göhde, 1973; Büchner, 1974). 
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Figure 2.2. 
ША-HISTOGRAMS OF NORMAL LEUCOCYTES AND NORMAL BONE-MARROW 
Lb •Ai' \.. 
\ 
I -1 '^  
DNA 
2n DNA 
DNA-histogram, obtained by pulse-cytophotometry of 18.000 periphe­
ral blood leukocytes (a) and of 48.000 bone marrow cells (b) of a 
normal person. The dotted line is a ten-fold magnification of the 
original curve. On the abcissa the relative nuclear DNA-content 
is plotted, on the ordinate the number of cells. 
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2,5. EVALUATION OF DNA-HISTOGRAMS 
The percentage of cells in the different phases of the cell 
cycle can be calculated from DNA-histograms by different mathema-
tical techniques. Dean and Jett (1974) developed a computer-based 
mathematical model. Göhde (1973) described a planimetrical method, 
which is used in this study. The percentage of S-phase cells is 
calculated from the distance on the abcissa between the middle of 
the G.-peak (denoted as X1 in figure 2.3) and the G2+M-peak ^ ) , 
multiplied by the height of the curve at half distance between the 
G,- and Gj+M-peak (y ). This simple estimation of the S-phase 
compartment (the dotted area in figure 2.3) reveals generally the 
same percentages of S-phase cells in bone-marrow histograms, as 
can be obtained by more sophisticated computer programs (Linden 
et al., 1974). 
After subtraction of the S-phase compartment, the percentages of 
G,- and G^+M-phases can be determined by planimetry of the remain-
ing areas of the graph in the 2n and 4n region respectively. 
F i g u r e 2 . 3 . 
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CHAPTER 3 
THE PREPARATION OF BONE-MARROW CELLS 
FOR PULSE CYTOPHOTOMETRY 
3.1. INTRODUCTION 
The reliability of DNA-measurements in bone-marrow cells by 
means of pulse cytophotometry largely depends on cell-processing 
methods, which provide a specific and quantitative staining of 
the nuclear DNA-content of single cells in suspension. If by clum-
ping or by coincidence two or more cells pass simultaneously the 
measuring field of the pulse cytophotometer , they are erroneous-
ly analysed as one particle with a fluorescence intensity appro-
ximately equal to the sum of the single pulses of each cell. 
To avoid cell-clumping, Trujillo and Van Dilla (1972) applied 
sonication of the suspension. Tobey et al. (1972) dispersed the 
cells with trypsin. For this purpose Berkhan (1972) introduced a 
peps in-treatment of the cells. 
The combination of this latter method with ethidium bromide 
staining of DNA was proposed by Göhde et al. (1972) . 
The preparation of bone-marrow cell suspensions in this study 
was performed according to the method described by Göhde (1973) 
with only slight modifications. Some essential steps in this me-
thod are discussed in this chapter. 
Since a method for a direct chemical measurement of the DNA-
content in single cells is not available, the validity of pulse 
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cytophotometric results has to be confirmed by comparison with 
the results of other indirect methods like micro-cytophotometry 
(Müller et al., 1972, 1974) and autoradiography (Linden et al., 
1974). In this study the validity of the method was tested by 
comparison of the percentage of S-phase cells obtained by pulse 
cytophotometry and autoradiography in normal and leukemic bone-
marrow samples. 
3.2. MATERIAL AND METHOD 
The preparation method, used for pulse cytophotometric measure-
ments of bone-marrow samples, consists of the following consecu-
tive procedures. 
I Processing and fixation of bone-marrow cells. 
1. Suspend 0.2-0.4 ml of a fresh aspirated bone-marrow sample in 
0.4 ml of ACD-solution (acid citrate dextrose, pH 7.0 , formula 
A, U.S.P. XV) 
2. Add for sedimentation of the erythrocytes 0.3 ml of 5% Dextran-
solution (Poviet, M= 200.000) in saline and mix by inversions. 
3. Incubate the sample for 30 minutes at 370C in a glass tube 
placed at an angle of 45°. 
4. Aspirate supernatant with a Pasteur pipette and suspend this 
in 15 ml of saline. 
5. Centrifuge for 7 minutes at 1000 χ g. 
6. Suck off supernatant and resuspend the cell-pellet in 1 ml of 
saline. 
7. Count the number of nucleated cells/ml. 
8. Add cell suspension by drops to 20 ml of aethanol 96% (-20oC). 
9. Store fixed cells in aethanol at -20oC. 
II Pepsin - treatment and cell staining with ethidium bromide. 
1. An amount of the cell suspension in aethanol, containing appro­
ximately 1 χ 10 cells,is centrifuged for 7 minutes at 1000 χ g. 
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2. Suck off supernatant, resuspend cell-pellet in 15 ml of sa­
line and centrifuge for 7 minutes at 1000 χ g. 
3. Suck off supernatant and resuspend cell-pellet in 10 ml pep­
sin-solution (0.5% pepsin, 1000 I.U./g - Merck, dissolved in 
saline, and adjusted to pH 1.5 with 1 N HCl.). 
4. Incubate for 25 minutes at 37 C. 
5. Centrifuge for 7 minutes at lOOOxg and suck off supernatant. 
6. Resuspend cell-pellet in 10 ml of ethidium bromide solution 
(25 mg/1 ethidium bromide. Serva, in 0.1 M NaCl buffered to 
pH 7.6 with 0.1 M Tris-HCl). 
7. Measurement in pulse cytophotometer between 1-24 hours of 
staining. Staining performed in the dark at room temperature. 
3.3. CONSIDERATIONS ABOUT THE METHOD 
Different steps in the preparation might erroneously influen­
ce the ultimate measuring results. 
Especially selective loss or destruction of cells, and variations in 
the staining reaction, caused by the preparation, would change the 
proportions in the histograms. 
The described method provided valid and reproducible results of 
pulse cytophotometric measurements of the cell cycle phases in bone-
marrow samples. Data about this method from the literature and 
fron own studies are discussed below. 
3.3.1. Anticoagulant 
A buffered acid citrate dextrose (ACD)-solution, used common­
ly for transfusion blood, was chosen as anticoagulant. ACD in con­
trast to heparin does not cause clumping of leucocytes (Cutts, 
19 70) and to our experience the morphology of bone-marrow cells in 
smears is better preserved with this anticoagulant than with hepa­
rin or EDTA. Actually a particular anticoagulant seems not 
essential for the method. Results similar to ours were obtained 
with heparin (Büchner, 1972; Müller et al. 1974). 
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3.3.2. Sedimentation of erythrocytes 
The contamination of a bone-marrow sample with a large number 
of erythrocytes appeared to result in a broadening of the peaks 
in the histograms. 
Pulse cytophotometric measurements of an erythrocyte suspension, 
stained with ethidium bromide, show only a small number of aspe-
cific fluorescence signals of low intensity. The mechanism by 
which erythrocytes apparently influence the measurement or the 
staining reaction is not understood. The reproducibility and the 
interpretation of bone-marrow histograms improve considerably af-
ter removal of the bulk of erythrocytes. Büchner et al.(1974) re-
ported similar observations. 
The removal of the erythrocytes was performed by dextran-se-
dimentation. Dextran induces rouleaux-formation of erythrocytes, 
which accelerates the sedimentation, whereas the leukocyte-sedi-
mentation-rate is unaffected (van Leeuwen et al., 1964; Cutts, 
1970). After sedimentation for 30 minutes, from normal bone-mar-
row samples a supernatant is obtained which contains bone-marrow 
cells and erythrocytes in approximately equal numbers. This redu-
ced erythrocyte-contamination appeared to be acceptable. The con-
tamination with erythrocytes in leukemic bone-marrow is after sedi-
mentation usually smaller than in normal samples. 
This sedimentation procedure causes a certain loss of bone-mar-
row cells. The recovery of bone-marrow cells in the supernatant, 
which is pipetted off, appeared to be 75 + 10 per cent of the ini-
tial values in normal (n= 15) as well as in leukemic (n= 15) sam-
ples. The residual cells were entrapped in the sediment. Compari-
son of differential cell counts in the initial bone-marrow samples 
with those after sedimentation revealed that no selective loss of 
particular cell types occurs. Differentiations of 400 cells in 
each of 10 normal and 15 leukemic bone-marrow samples showed no es-
sential differences before and after dextran-sedimentation. 
Erythrocytes can also be removed from bone-marrow samples by 
selective lysis, for instance with ammonium chloride (Boyle, 1968; 
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Cutts, 1970). To investigate the eventual effects of dextran-se-
dimentation on pulse cytophotometric measurarents, histograms of 
various bone-marrow samples after dextran sedimentation were com­
pared to histograms of the same samples after ammonium-chloride 
lysis (table 3.1). The results obtained by both methods were not 
significantly different (Wilcoxson test). 
After ammonium chloride, however, the cells rapidly lose their 
staining ability, even when fixed in aethanol. 
3.3.3. Centrifugation 
In this method the cells are centrifugea four times, once 
before fixation and three times after fixation. Centrifugation 
causes loss of cells and increases cell-clumping. At lower speed 
(600 χ g for 7 minutes) a seJective loss of small bone-marrow cells, 
reflected by changes in differential cell counts, occurred in 
some samples. At higher centrifugation speeds (1000 χ g and 1500 
χ g for 7 minutes) the cell loss appeared to be smaller and not 
selective for any type of cell within a given normal or leukemic 
bone-marrow sample. The recovery of bone-marrow cells after cen-
trifugation at 1000 χ g for 7 minutes, before fixation, was 
9 0 + 4 per cent in normal samples (n= 11) and 9 5 + 3 per cent in 
leukemic samples (n = 12). 
A selective loss of cells of a particular size might change 
the percentages of cells in the different cell cycle phases in 
the histograms, because generally cells in S- and G_+M-phase are 
larger than in G.-phase (Haag, 1971; Crissman and Steinkamp, 1973). 
This was investigated by comparing histograms of various bone-mar­
row samples after centrifugation at different speeds (table 3.II). 
The higher percentage of S-phase cells in samples after centri­
fugation at 600 χ g might be consistent with the observed loss of 
smaller bone-marrow cells. 
The results after centrifugation at 1000 or 1500 χ g were not sig­
nificantly different (Wilcoxson test). 
Clumping of bone-marrow cells increases with higher centrifugation 
speed and with longer duration of centrifugation (Cutts, 1970) 
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Table 3.1 
COMPARISON OF HISTOGRAMS AFTER DIFFERENT METHODS FOR ERYTHROCYTE 
REMOVAL 
sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Dextran 
S 
3,0 
4,4 
5,8 
6,0 
9,0 
12,2 
12,1 
15,4 
16,2 
19,4 
20,4 
22,2 
sedimentation 
G2+M 
0,8 
1.0 
1,8 
2,7 
2,7 
3,3 
4,0 
3,2 
4,3 
7,3 
8,4 
6,3 
Ammonium 
lysis 
S 
3,0 
4,7 
6,7 
6,1 
9,8 
12,1 
11,5 
16,2 
15,8 
20,0 
20,1 
22,0 
chloride 
G2+M 
0,8 
1,0 
2,0 
2,8 
3,1 
3,2 
3,9 
2,8 
5,0 
7,8 
9,0 
5,6 
Comparison of the percentages of bone-marrow cells in S- and 
G^+M-phase in DNA-histograms after dextran sedimentation of ery-
throcytes and after selective lysis of erythrocytes with ammo-
nium chloride. Samples 1-9 were obtained from patients with acute 
leukemia in various stages of the disease. Samples 10-12 showed 
normal morphology. The values were not corrected for contamina-
tion with peripheral blood cells. 
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Table З.ІІ 
VARIATION OF CENTRIFUGATION-SPEED 
sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
бООхд 
S 
2,2 
3,7 
5,7 
6,5 
10,7 
12,6 
14,2 
14,6 
17,6 
18,1 
19,0 
G 2+M 
1,2 
2,9 
1,5 
1,2 
1,7 
3,5 
2,6 
3,8 
4,0 
3,7 
5,0 
lOOOx 
s 
1,8 
3,2 
5,5 
6,2 
10,7 
12,4 
11,7 
12,8 
14,9 
17,6 
15,1 
g 
G 2+M 
0,9 
2,6 
1,3 
0,9 
2,1 
3,3 
2,3 
3,9 
3,7 
3,8 
4,4 
ISOOxg 
S 
2,2 
3,5 
5,9 
6,5 
10,1 
12,3 
11,2 
12,6 
14,5 
17,8 
14,8 
G 2+M 
0,8 
2,9 
1,4 
1,4 
2,2 
3,8 
3,3 
3,7 
3,3 
3,6 
4,6 
Comparison of the percentages of bone-marrow cells in S- and 
G2+M-phase in DNA-histograms after centrifugation at 600, 1000 or 
1500 χ g for 7 minutes. The samples 1-4 contained >90% of blast 
cells;in the samples 5-11 various types of bone-marrow cells were 
seen. 
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Empirically centrifugation for 7 minutes at 1000 χ g appeared 
to be suitable for the different centrifugation-procedures of this 
method. 
3.3.4. Fixation 
Aethanol provided stable fixation of the bone-marrow cells 
for a long time. Histograms of the same bone-marrow samples/fixed 
from 20 minutes up to several months,showed no noticeable diffe­
rences . 
3.3.5. Incubation with pepsin 
Treatment of the cells with pepsin, according to the method 
of Berkhan (1972) to prevent cell clumping,also results in a dis­
appearance of the cytoplasma. In a phase-contrast microscope or a 
fluorescence microscope only naked nuclei are seen after pepsin 
digestion of the cytoplasma of bone-marrow cells. A similar effect 
was observed in other different cell types (Göhde, 1972; Sprenger 
et al., 1972). The nuclei, which probably have a much lower dum-
ping-tendency than intact cells, remain single in suspension. The 
effect of a pepsin treatment is demonstrated in figure 3.1. Histo-
gram "A" was obtained from fixed lymphocytes which were centrifu-
gated for 15 minutes and stained directly with ethidium bromide. 
A considerable number of fluorescence pulses are registrated be-
tween 4n and 6n, and in the 6n - area. These pulses, apparently 
due to cell- clumping, disappeared after pepsin treatment (histo-
gram "B") . 
The concentration of pepsin, the incubation times and the pH of 
the pepsin-solution were varied individually. At higher concentra-
tions of pepsin (1.0 and 2.0 per cent) a considerable number of 
the nuclei is ruptured, resulting in severe cell loss. At lower 
concentrations (0.1 and 0.2 per cent) cell clumping is only partial-
ly prevented. Variation of the incubation time appeared to be 
less critical. The percentages of G,-, S- and G2+M-phases in the 
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Figure 3.1. 
EFFECT OF PEPSIN ON CELL CLUMPING 
DNA 
Disappearance of fluorescence signals >4n, caused by cell clumps, 
in the DNA-histogram of lymphocytes after pepsin treatment. For 
histogram "A" the lymphocytes were stained directly after fixa-
tion in aethanol. Histogram "B" was obtained after pepsin-treat-
ment of the fixed lymphocytes before staining with ethidium bro-
mide. The thin line is a ten-fold magnification of the original 
curve. 
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histograms were not different after pepsin incubation for 15, 25 
or 35 minutes. The same was observed for variation of the pH be-
between 1.5 and 1.8. 
A disadvantage of the pepsin-treatment is the loss of cell 
morphology, so that a morphological control of the samples is im-
possible. Eventual selective loss of particular cell types by 
pepsin at low pH would influence the measuring results. This was 
investigated by comparing DNA-histograms of various bone-marrow 
samples after pepsin-treatment and after sonication of the cells, 
Sonication of cells, not treated with pepsin, largely reduces 
cell clumping as can be seen from the absence of 6n-signals in 
the histograms (Trujillo and Van Dilla, 1972) . The histograms ob-
tained by both methods (table 3.III) were in good agreement. In 
most histograms after sonication a slight number of signals is 
still present between 4n and 6n, probably representing cell clumps 
not fully dispersed by sonication. This may also explain the 
small difference of the percentages of G2+M-phase cells in some 
samples. 
Occasionally bone-marrow samples show even without pepsin 
treatment no dumping of cells after aethanol fixation. Evidence 
for this is the absence of fluorescence signals >4n in histograms, 
obtained before pepsin-treatment. Additional treatment with pep-
sin did not change the percentages of G.-, S- and G2+M-phase 
cells in these histograms, which confirms the absence of selec-
tive loss of cells or changes in the staining reaction by pepsin 
at low pH. 
3.3.6. Staining with ethidium bromide 
The fluorochrome ethidium bromide binds specifically to 
nucleic acids, probably by intercallation in double-stranded DNA 
and RNA. This binding results in a 20- to 25- fold increase of 
the fluorescence quantum efficiency of the dye. In consequence 
the intensity of fluorescence emission increases by a factor be-
tween 50 to 100 (Le Pecq and Paoletti, 1966, 1967). The degree 
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Table З.ІІІ 
COMPARISON OF HISTOGRAMS AFTER PEPSIN-INCUBATION OR SONICATION 
sample 
1* 
2* 
3* 
4 
5* 
6* 
7 
8 
9* 
10 
11 
12 
13 
pepsin 
S 
4,4 
5,4 
7,5 
8,4 
8,8 
10,0 
10,9 
11,0 
12,0 
12,7 
15,5 
17,2 
17,4 
G 2+M 
1,0 
2,0 
2,0 
1,7 
1,7 
2,6 
2,3 
2,6 
4,1 
3,1 
4,1 
2,7 
3,8 
sonication 
S 
4,0 
5,1 
8,4 
9,2 
8,9 
9,1 
9,5 
12,4 
11,1 
12,5 
16,6 
15,8 
17,6 
G 2+M 
1,2 
1,7 
2,4 
2,9 
1,5 
2,6 
2,4 
2,8 
4,7 
4,3 
3,5 
3,9 
4,0 
Comparison of the percentage of bone-marrow cells in S- and 
Gp+M-phase in DNA-histograrre after treatment of the cells with 
pepsin or sonication. The pepsin method is described in the text, 
sonication of stained cells was applied for 10 seconds at 100 
watts in a 10 ml volume (Sonifier, M.S.E.-7100.-) 
*= samples wüh a high percentage of blast cells. 
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of fluorescence of the bound ethidium bromide is proportional to 
the amount of DNA present, under suitable pH- conditions , ionic 
strenghth and temperature (Le Pecq, 1971). The specificity and 
proportionality of ethidium bromide staining of DNA was confirmed 
in liver cells by Sprenger et al. (1972). Prasad et al. (1972) 
and Blackburn et al. (1973) demonstrated the suitability of ethi-
dium bromide for quantitative staining of the cellular DNA-con-
tent in a variety of tissues. Müller et al. (1972,1974) proved 
this to apply to bone-marrow cells by comparing both micro- and 
pulse cytophotometric results obtained after staining with ethi-
dium bromide and after acriflavin-Feulgen-staining. 
Pepsin treatment of the cells did not influence the specificity 
and the proportionality of the staining reaction (Sprenger et al., 
1972) . 
Le Pecq and Paoletti (1966) observed a linear relationship 
between the fluorescence intensity of ethidium brcmide and the con-
centration of DNA in solutions. If a linear proportionality exists 
between the fluorescence of DNA stained with ethidium bromide and 
the quantity of nuclear DNA per cell, the ratio of the mean fluo-
rescence intensity measured in diploid and tetraploid cells should 
be 1:2. In fact Sprenger et al. (1972) obtained a ratio of 1:2.11, 
Haag (19 73) reported a ratio of 1:1.8; Göhde (1973) and Büchner 
(1974) observed a ratio of 1 : 2. 
In our experiments a ratio of 1.88 + 0.04 (n=70) was observed. 
Deviations of linearity can be caused by partial absorption of 
fluorescence emission light related with spatial quenching and by 
variations in chromosomal density during the cell cycle (Haag, 
1973). 
Besides DNA also RNA is stained by ethidium bromide. However 
after pepsin digestion at most some nuclear-RNA remains. Addi-
tional incubation of the cells for one hour with 0.1% RNAse-so-
lution did not change the bone-marrow histograms. Probably only 
a small fraction of the total fluorescence of the nuclei derives 
from nuclear RNA. Similar observations were published by Sprenger 
et al. (1972) . 
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3.4. VALIDITY OF THE METHOD 
The percentage of S-phase cells, obtained by pulse cytophoto-
metry and autoradiography of the same bone-marrow samples were 
compared. The method of autoradiography and some essential results 
are described in a previously published paper, which is presented 
as a whole in chapter 4. Therefore materials and method of auto­
radiography are not described in this chapter . 
A close correlation is found between the results obtained by pulse 
cytophotometry and autoradiography (table 3.IV). The non-parame­
tric rank correlation coefficient (Spearman) calculated between 
the values found by both methods was significantly positive (r= 
0.95, n= 29, ρ <0.001). The percentages of S-phase cells obtained 
by both methods were not significantly different in the 29 samples 
as a whole (Wilcoxson test). Separately calculated, the S-phase 
percentages were not significantly different in the samples with 
normal morphology and in those of patients with AML. The S-phase 
values for the samples of patients with ALL correlated well 
(r= 0.99, n= 7, ρ <0.001) but the values obtained by autoradio­
graphy were significantly lower (p <0.05; mean and standard devia­
tion for pulse cytophotometry: 15.1 + 5.6%, for autoradiography: 
13.2 +5.1%). This difference can be due to the presence of U-cells, 
which are found occasionally in leukemic bone-marrow (Ernst, 1973) 
or simply related to test-circumstances and criteria of labeling. 
Evidence for the validity of the method is also demonstrated 
by the fact that pulse cytophotometric results in normal and leuke­
mic bone-marrow, as reported in the subsequent chapters, are in 
agreement with findings obtained by other techniques reported in 
the literature. 
3.5. VARIABILITY OF PULSE CYTOPHOTCMETRIC MEASUREMENTS 
The variability of pulse cytophotometric measurements was in­
vestigated by preparing multiple cell suspensions from the same 
bone-marrow sample, repeating the whole procedure of sedimentation, 
* 
U-cells i.e. unlabeled cells with a DNA-ccntent between 2n and 4n are discus­
sed in section 6.4 (p.109) 49 
Table З.І 
PULSE CYTOPHOTOMETRY COMPARED WITH AUTORADIOGRAPHY 
S a m p l e 
N o r m a l 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
A . M . L . 
1 1 
12 
1 3 
14 
15 
16 
17 
18 
19 
20 
2 1 
2 2 
A . L . L . 
2 3 
24 
2 5 
2 6 
2 7 
2 8 
2 9 
% b l a s t c e l l s 
i n t h e 
b o n e - m a r r o w 
> 9 0 
> 9 0 
> 9 0 
> 9 0 
> 9 0 
> 9 0 
6 0 
80 
> 9 0 
> 90 
> 9 0 
5 2 
> 90 
50 
> 90 
6 0 
6 5 
> 90 
6 0 
S - p h a s e (%) 
i n D N A - h i s t o g r a m s 
2 4 . 0 
2 5 . 2 
2 5 . 6 
2 5 . 7 
2 6 . 0 
2 6 . 2 
2 7 . 4 
2 6 . 0 
2 3 . 6 
2 5 . 8 
4 . 6 
5 . 6 
6 . 9 
7 . 0 
9 . 5 
1 3 . 5 
1 7 . 8 
1 8 . 3 
1 9 . 8 
2 0 . 0 
2 3 . 6 
2 8 . 6 
7 . 0 
1 0 . 8 
1 2 . 9 
1 4 . 5 
1 6 . 5 
2 1 . 7 
2 2 . 3 
Label ing i n d e x (%) 
w i t h H - t h y m i d i n e 
2 3 . 3 
2 5 . 3 
2 5 . 5 
2 6 . 6 
2 6 . 9 
2 3 . 6 
2 7 . 0 
2 5 . 6 
2 4 . 3 
2 4 . 7 
4 . 2 
4 . 4 
9 . 0 
7 . 2 
6 . 6 
1 3 . 1 
1 9 . 0 
1 6 . 3 
1 9 . 0 
2 0 . 5 
2 0 . 2 
2 3 . 2 
4 . 3 
1 1 . 5 
1 1 . 6 
1 2 . 8 
1 5 . 0 
1 6 . 4 
2 0 . 9 
Percentage of S-phase cells calculated from DNA-histograms compared 
to the labeling indices obtained with autoradiography of the same 
bone-marrow samples of patients with a normal morphology of the 
bone-marrow, and of patients with A.M.L. or A.L.L. during various 
stages of the disease 
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Table З. 
VARIABILITY OF DNA-HISTOGRAMS 
Sample 
1 
2 
3 
4 
5 * 
Diagnosis 
A.L.L. 
remission 
of A.M.L. 
remission 
of A.M.L. 
A.M.L. 
A.L.L. 
Number 
7 χ 
9 χ 
9 χ 
7 χ 
11 χ 
G 1 + S.D. 
C.V.% 
89.8 + 0.5 
0.65 
77.9 + 0.7 
0.92 
75.0 + 0.4 
0.51 
72.9 + 1.0 
1.37 
64.6 + 0.9 
1.45 
S + S.D. 
C.V.% 
8.0 + 0.5 
6.73 
17.3 + 0.3 
1.45 
20.9 + 0.3 
0.37 
20.3 + 0.5 
2.56 
21.9 +0.9 
4.36 
G.+M + S.D. 
C.V.% 
2.2 + 0.2 
6.74 
4.9 + 0.5 
11.10 
3.7 + 0.3 
7.87 
7.6 + 0.6 
8.03 
13.6 + 0.8 
5.38 
Variability of DNA-hlstograms demonstrated by standard deviation 
(S.D.) and coefficient of variation (C.V. ) The whole procedure of 
sedimentation, fixation, pepsinisation, washing and staining was 
repeated various times with the same bone-marrow samples as star­
ting material. 
The values are not corrected for contamination with peripheral 
blood cells. 
•sample 24 hours after adriamycin 
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fixation, pepsinisation and staining. The different cell prepa-
rations, obtained from the same marrow, were measured at various 
times after fixation. In each sample approximately 10 cells were 
measured. The results are shown in table 3.V. 
The standard deviations are rather low; the coefficients of varia-
tion of the G.-measurements were 0.5 - 1.5 per cent. Coefficients 
of variation in S-phase cells were higher, with a maximum of 6.7 
per cent. The coefficients of variation of the Gj+M-compartment 
amounted to 11.1 per cent. Considering these variations, the cal-
culated percentages of bone-marrow cells in the different cell 
cycle phases were rounded and are presented as whole figures in 
the subsequent chapters. 
3.6. COMPLICATING FACTORS IN THE EVALUATION OF DNA- HISTOGRAMS 
3.6.1. Admixture of peripheral blood cells in bone-marrow samples 
Bone-marrow samples can be variously contaminated with peri-
pheral blood cells. Because all mature peripheral leukocytes are 
diploid, this contamination results in an increase in the percen-
tage of G,-phase cells in the histograms and hence a decrease in 
the fractions of S- and G_+M-phase cells. Therefore, the percen-
tages of the cell cycle phases, calculated from the bone-marrow 
histograms, are corrected for the amount of trapped peripheral 
blood cells. In practice the correction is made for the percentage 
of lymphocytes and segmented granulocytes counted in smears of 
the bone-marrow samples under investigation. In smears of normal 
bone-marrow this percentage varies from 10 to 45 per cent, which 
is in agreement with data in the literature (Dacie and Lewis, 1968) . 
In the blood of patients with acute leukemia, contaminating 
blast cells from peripheral blood can not be differentiated from 
marrow-blast cells by morphological methods. The proliferative ac-
tivity of these peripheral blast cells is lower than the prolifera-
tive activity of bone-marrow blasts (Killmann, 1968). In table 3.VI. 
this difference is illustrated by pulse cytophotometric findings 
in the bone-marrow and the blood of leukemia patients with a high 
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Table З. І 
PROLIFERATION-PATTERNS IN BONE-MARROW AND PERIPHERAL BLOOD 
Diagnosis 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.L.L. 
A.M.L. 
A.M.L. 
A.L.L. 
Bone-marrow 
% blast cells 
>90 
80 
>90 
>90 
>90 
>90 
>90 
>90 
>90 
>90 
>90 
S 
4 
4 
6 
9 
10 
11 
12 
12 
13 
15 
19 
G 2+M 
1 
1 
1 
2 
2 
3 
3 
4 
2 
5 
3 
Peripheral blood 
% blast cells 
90 
80 
>90 
>90 
>90 
>90 
80 
>90 
>90 
>90 
>90 
S 
2 
2 
1 
3 
6 
5 
1 
6 
2 
7 
3 
G 2+M 
1 
1 
1 
1 
1 
1 
1 
2 
1 
2 
1 
Percentages of bone-marrow cells in S- and Gj+M-phase compared to 
the percentages of S- and G2+M-phase cells in the peripheral blood 
at the same time. The samples were obtained from patients with a 
high percentage of blast cells in the bone-marrow and the blood, 
during various stages of acute leukemia. 
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percentage of peripheral blast cells. Contamination of leukemic 
bone-marrow samples with peripheral blast cells will obviously de-
crease the percentage of S- and G2+M-phase cells in the bone-mar-
row histograms. In patients with a high percentage of blast cells 
in the blood, the degree of this dilution is not measurable. To 
some extent the same problem is encountered in autoradiography and 
micro-cytophotometry. Only large variations of contamination can 
be avoided by proper bone-marrow puncture, which provides a sam-
ple with numerous bone-marrow fragments. The variation of pulse-
cytophotometric results,due to peripheral blast cell contamina-
tion,was investigated by comparing the histograms of two bone-
marrow samples aspirated at different sites. In fact the histo-
grams of these repeated samples in patients with acute leukemia 
showed generally comparable results (table 3.VII). 
3.6.2. Coincidences 
Coincidence is defined as the simultaneous passage by chance 
of two or more cells through the measuring field of a flow system. 
As mentioned above, coincidences can influence the measuring re-
sults. The number of coincidences in the pulse cytophotometer is 
essentially related to the measuring rate (Göhde,1973). All mea-
surements in this study were performed at a relative low rate of 
250 cells per second, which results in a statistical chance for 
coincidences of less than 0.5 per cent (Göhde, 1973) . Considering 
this low value, a correction of the measurements for coincidences 
is not made. 
3.7. CONCLUSION 
In the described method two major problems are encountered: 
cell clumping and cell loss. An effective avoidance of cell clum-
ping is attained by pepsin treatment of the cells, however at the 
expense of cell morphology. Cell counts before and after the en-
tire procedure indicate a loss of 25 to 50 per cent. About half 
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Table З. ІІ 
COMPARISON OF BONE-MARROW SAMPLES ASPIRATED AT DIFFERENT SITES 
Patient 
V.A. 
B.M. 
V.DU. 
W.W. 
V.R. 
J.H. 
F.L. 
M.B. 
M.E. 
P.W. 
V.H. 
Diagnosis 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
Sample I 
S 
2 
5 
6 
8 
12 
12 
13 
4 
6 
10 
12 
G 2+M 
1 
2 
1 
2 
3 
3 
2 
2 
1 
2 
4 
Sample II 
S 
1 
6 
9 
7 
14 
12 
13 
6 
5 
8 
11 
G 2+M 
1 
1 
2 
3 
4 
2 
3 
2 
1 
1 
3 
Comparison of the percentages of cells in S- and in G^+M-phase 
in DNA-histograms of bone-marrow samples, aspirated at different 
sites (manubrium sterni, corpus sterni or crista iliaca). The 
time interval between the aspiration of two samples was 1 or 2 
days. All samples contained a high percentage of blast cells. All 
patients, except M.B. and P.W., were untreated. 
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occurs during dextran sedimentation of the erythrocytes. In later 
steps cell loss is minimized by proper choice of centrifugation 
speed. This cell loss, however,appears not to be selective for 
particular types of cells. 
The close correlation between pulse cytophotometric and autoradio-
graphic results confirms the validity of the method, used in this 
study, for the determination of S- phase cells. The agreement of 
the pulse cytophotometric results in normal- and leukemic bone-
marrow with findings by different other techniques in the litera-
ture »indicates the validity of the method for the different cell 
cycle phases. 
Although the results appear valid and reproducible, the dis-
advantages of the present method like cell loss, the loss of 
morphology and the complications by various admixture of peripheral 
blood cells are obvious. The development of refined methods for 
the dispersal and the staining of the cells, combined with cell 
separation methods,will undoubtedly improve the possibilities of 
pulse cytophotometry for cell cycle analysis in bone-marrow. 
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Chapter 4 
BONE-MARROW-PROLIFERATION 
PATTERNS IN ACUTE MYELOBLASTIC 
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SUMMARY 
The proliferation patterns of normal and leukaemia bone-mar-
row were studied by measuring the D.N.A. content of large numbers 
of cells by pulse cytophotometry (P.C.P.). In nineteen normal 
bone-marrow samples an average of 66.3% of the bone-marrow cells 
were in the G. phase (2n D.N.A.), 26.1% in the S phase (2n <D.N.A. 
<4n) and 7.5% in G2+M phase (4n D.N.A.). The percentages of S-
phase cells determined by autoradiography and P.C.P. correlated 
well, both in normal and in leukaemia bone-marrow. In 25 patients 
with untreated acute myeloblastic leukaemia (A.M.L.) lower percen-
tages of cells were found in S and G^+M phases, indicating a smal-
ler proliferating pool compared with normal bone-marrow. The like-
lihood of a complete remission being attained in A.M.L. with the 
first treatment course was correlated with the percentage of S-
phase cells present before treatment. At remission in A.M.L. the 
proliferation pattern was restored to normal. 
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INTRODUCTION 
Pulse Cytophotometry (P.С.P.) of a stained bone-marrow cell 
suspension provides information about the D.N.A. content distri­
bution in large numbers of single cells. The ability to do 
measurements on 10 cells in a few minutes permits a statistical 
reliability which is not obtainable with other methods. Since 
cells in the different phases of the cell cycle are characterised 
by a particular D.N.A. content , the percentages of cells in G1, 
S, and Gp+M phases can be calculated from P.C.P. measurements. The 
relative amounts of cells in these phases reflect the prolifera­
tive activity of the cell population. We have compared P.C.P. with 
autoradiography to test the validity of this new method for the 
study of cell-proliferation patterns and report the results of 
P.C.P. on bone-marrow cells in acute myeloblastic leukaemia (А.М.ІД 
MATERIAL AND METHODS 
Preparation of Cell Suspensions 
0.2-0.5 ml of freshly aspirated bone-marrow was mixed with an 
equal volume of acid-citrate-dextrose (A.CD.) (formula A). The 
red blood-cells sedimented by gravity in 30 minutes, after addi­
tion of dextran solution (molecular weight 200,000, final concen­
tration 1%). The supernatant was pipetted off and diluted with sa­
line solution. The cells were spun at 1000 g for seven minutes. 
After resuspension in saline the cells were fixed in 20 ml of etha­
nol and stored at -20OC. Before P.C.P. the fixed cells were washed 
in saline and the cell cytoplasm was digested by 0.5% pepsin 
(pH 1.5) for 25 minutes at 370C. The cells were stained with ethi-
dium bromide (Serva 25 mg. per litre in "Tris" HCl buffer pH 7.б)8-9 
Measurement of D.N.A. Content 
The fluorescence of specifically D.N.A.-bound dye was mea­
sured with the impulse-cytophotometer (I.C.P.-ll, Phywé, Göttin-
gen, West Germany). The percentage of diploid (2n) G, cells, te-
traploid (4n) G2+M cells, and interploid (2n<DNA<4n) S phase 
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cells was calculated from the D.N.A. histograms by planimetry. 
Data were corrected for trapped blood-cells counted in the simul­
taneously prepared marrow smears. 
Autoradiography 
Freshly aspirated bone-marrow, mixed with A.CD. solution, 
was incubated at 370C for one hour with Η-thymidine (specific 
activity 5 Ci per mmol, final concentration 5 yCi per ml). Smears 
were prepared, air-dried, fixed in methanol, and stained by the 
May-Grunwäld- Giemsa technique. The smears were then covered 
with polyvinyl-chloride to prevent chemography of the over-layer-
ed Ilford L4 photographic emulsion. The autoradiographs were 
examined after an exposure of seven days at 4 C. The percentage of 
labelled cells (labelling index) was determined by counting at 
least 2000 bone-marrow cells. Cells with >4 grains were consider-
ed labelled. 
Patients 
25 Consecutive patients referred with A.M.L. were studied. 
The diagnoses were confirmed at the W.H.O. Reference Centre for 
Leukaemias, Villejuif, France. All A.M.L. patients on first diag-
nosis were treated with cytarabine (cytosine-arabinoside) alone 
or in combination with thioguanine or daunorubicin (daunomycin), 
* 12 
according to the L.A.M. -2 protocol of the E.O.R.T.C. 
RESULTS 
Normal Findings 
All normal peripheral-blood leucocytes were equal in D.N.A. 
content, the amount corresponding to the diploid stats of non-pro-
liferating cells. Normal bone-marrow, on the other hand, contained 
cells in G,, Gy+M, and S phases. The distribution, in nineteen sam-
ples of bone-marrow from 15 haematologically normal controls, was 
(mean + S.D.):66.3+1.9% in G, phase, 26.1+1.9% phase, and 7.5+0.8% 
G2+M phase. The reproducibility of P.C.P. measurements, including 
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c e l l processing and s t a i n i n g , was good. Standard deviations of percen­
tages of G,, S, and G^ +M c e l l s , c a l c u l a t e d from 10-20 repeated mea­
surements of the same samples,varied from 0.3 to 1.0%, and coef­
f i c i e n t s of v a r i a t i o n varied from 1.5% for G. to 11.1% for G9+M. 
P.C.P. Compared with Autoradiography 
The percentages of S-phase cells found by P.С P. were com­
pared with the labelling indices determined in the same bone-mar­
row samples. 29 Samples were examined of which 10 showed normal 
morphology; 12 samples were obtained from A.M.L. patients and 7 
from A.L.L. patients during various stages of the disease. The 
non-parametric rank correlation coefficient (Spearman), calculated 
between the values found by both methods,was highly significant­
ly positive (r= 0.95, n= 29, ρ <0.001). The percentages of S-phase 
cells found by both methods were not significantly different (Wil-
coxson's test). 
Proliferation Patterns in A.M.L. 
Patients with untreated A.M.L. had a lower percentage of 
cells in S and G?+M phases when compared with controls (table 4.1). 
The patients with the lowest amount of proliferating S and G_+M 
phase cells did not benefit from treatment, whereas all those 
with more than 15% of cells in S and G2+M phases did attain a 
complete remission, save patient 21 whose clinical course was 
complicated by a chloroma of the left orbital wall. 
When the first complete remission was attained, the bone-
marrow histogram showed mostly a normal proliferation pattern (table 
4.1). The remission lasted only a short time in patients 13, 15, 
and 24, who showed relative low percentages of S and Gj+M phase 
cells at the time when complete remission was achieved. 
In bone-marrow histograms of 13 A.M.L. patients with a first 
relapse, the percentages of S and G^+M phase cells were lower 
than normal and lower than the percentages found at the first re­
mission. Only 2 patients achieved a second complete remission. The 
relation between a high percentage of S-phase cells and the chance 
of complete remission after a relapse was less striking than at 
first diagnosis of A.M.L. (table 4.I),The survival-time after relapse 
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Table 
RESULTS OF Р.С.P. IN ACUTE MYELOBLASTIC LEUKAEMIA 
Patients 
V.A. 
T.W. 
H.S. 
S.E. 
B.V. 
P..M. 
A.K. 
J.v.D. 
J.Bo. 
S.W. 
V.H. 
P.Bi. 
J.B. 
P.C. 
J.S. 
K.J. 
V.R. 
A.D. 
U.D. 
M.M. 
J.M. 
G.B. 
K.T. 
R.L. 
H.M. 
W.P. 
H.R. 
W.R. 
P.B. 
normal 
Case 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
n=19 
1 
Sex 
d 
% 
ΰ 
Ç 
ç 
$ 
д 
d 
ci 
$ 
ϋ 
d 
d 
cf 
Cf 
Q 
ff 
ff 
Ç 
ff 
ff 
$ 
ff 
9 
ff 
ff 
$ 
ff 
ff 
Age 
(in years) 
52 
28 
67 
39 
59 
36 
20 
43 
34 
29 
22 
32 
33 
20 
16 
54 
64 
27 
39 
60 
16 
51 
45 
61 
65 
52 
39 
54 
33 
Р.СР. results 
before treatment 
Gl 
97 
95 
95 
94 
94 
93 
93 
93 
92 
90 
88 
88 
86 
85 
84 
82 
82 
80 
80 
78 
74 
73 
70 
69 
67 
II 
II 
" 
II 
66.3 
S 
2 
4 
4 
5 
5 
5 
5 
6 
6 
8 
9 
10 
10 
11 
13 
14 
14 
16 
15 
17 
21 
21 
23 
24 
26 
II 
" 
II 
II 
26.1 
G 2+M 
2 
2 
1 
2 
2 
2 
2 
4 
4 
3 
4 
4 
4 
5 
5 
5 
6 
7 
7 
7 
II 
II 
It 
II 
7.5 
Result 
of 
treatment 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
P.R. 
C R . 
C R . 
C R . 
C R . 
C R . 
C R . 
C R . 
F. 
C R . 
C R . 
C R . 
C R . 
F = failure 
P.R.= partial remission 
CR.= complete remission 
+ = still in remission at 1/1/75 
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4 . 1 
P.C:P. at time 
of complete 
remission 
S 
20 
25 
18 
It 
26 
27 
26 
25 
29 
27 
15 
27 
25 
25 
26 
24 
G2+M 
5 
6 
5 
II 
6 
6 
6 
8 
7 
8 
8 
8 
6 
6 
6 
7 
Duration of 
1st remission 
(in months) 
2 
4 + 
2 
II 
4 
18 
12 + 
ih 
4 
7 
10 
16 
9 
4 
4 
P.CP. at time 
of 1st 
relapse 
S 
22 
II 
10 
17 
11 
15 
10 
7 
II 
23 
24 
11 
10 
G2+M 
6 
II 
2 
4 
3 
3 
2 
3 
II 
5 
8 
3 
2 
Result of 
2nd 
remission 
induction 
F 
F 
CR. 
F 
F 
F 
F 
CR. 
F 
F 
F 
Survival 
after 
relapse 
(in months) 
8 
4 
18+ 
2 
4 
3 
1 
18 + 
6 
4 
4 
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seemed longer in patients with a relative active proliferating 
pool. 
DISCUSSION 
P.C.P. can provide an estimate of the nuclear D.N.A. content 
of a large number of bone-marrow cells within a short time: up to 
100.000 cells can be measured within two hours of bone-marrow as-
piration. The D.N.A. distribution histogram reflects the percen-
tages of cells in the different phases of cell cycle. Cells in G 
and G. phases contain the same amount of D.N.A. (2n). According 
13 14 
to some authors ' the non-proliferating G cells are quies-
cent or prolonged G, cells, and we have considered all cells with 
a 2n D.N.A. content to be G,. Cells in G« and M phases with a te-
traploid D.N.A. content (4n) cannot be differentiated by P.C.P., 
but the percentage of M-phase cells can be determined by counting 
the mitotic index of simultaneously prepared marrow smears. The 
main disadvantage of P.C.P. compared with autoradiography and mi-
crofluorometry is that the cell morphology is lost. 
P.C.P. results on normal bone-marrow accord with microfluoro-
metric observations in Feulgen stained bone-marrow smears and 
with the results obtainedby autoradiography. In some leukaemic 
bone-marrow samples a significant lower percentage of S-phase 
cells has been found by autoradiography; this could be due to the 
so-called U cells.3,17 
Almost all patients with untreated A.M.L. had a lower-than-
normal percentage of cells in S and G^+M phases. This finding re-
flects the larger pool of non-proliferating cells, described in 
13 14 advanced acute leukaemia. ' In the A.M.L. patients who had a 
relatively high percentage of S-phase cells before treatment, 
complete remissions were attained. This correlation might be due 
to the fact that the main cytostatic drug used was cytarabine, 
1 fi 1 9 
which is specifically active in S-phase cells. ' 
When a complete remission was achieved the bone-marrow pro-
liferation returned to a normal pattern. Three patients with low 
S and Gj+M percentages in morphological normal bone-marrow at 
68 
remission, relapsed early; the possibility of using P.C.P. for 
early detection of relapse will be investigated. 
In acute leukaemia P.C.P. provides information rapidly about 
bone-marrow proliferation before, during, and after chemotherapy. 
Monitoring of cellkinetic effects of cytostatic therapy by P.C.P. 
may improve treatment schedules and the prognosis of acute leu-
kaemia . 
69 
REFERENCES 
1. Göhde,W. in Fluorescence Techniques in Cell Biology (edited by 
A.A.Thaer and M.Sernetz); p.79. New York, 1973. 
2. Büchner,Th., Hiddeman,W., Schneider,R., Kamanabroo,D. Blut, 
1974, 1,1. 
3. Müller,D., Reichert,E., Lang,H.П., Orywall,D. Klin. Wschr. 
1974, 52, 384. 
4. Haanen,C., Hillen,H., Wessels,J. in Pulse-Cytophotometry (edi­
ted by C.Haanen, H.Hillen and J.Wessels). Ghent (in the press). 
5. Leading Article, Lancet. 1975, 1, 435. 
6. Vendrely,C. in The Cell Cycle and Cancer (edited by R.Baserga); 
p.227. New York, 1971. 
7. Berkhan,E. Ärtzl.Lab. 1972, 18, 77. 
8. Le Pecq,J.B. Methods Biochem. Anal. 1971, 20, 41. 
9. Sprenger,E., Böhm,Ν., Schaden,Μ., Kunze,M., Sandritter,W. His-
tochemie, 1972, 30, 255. 
10.Göhde,W. Habilitationsschrift. Münster, 1973. 
11.Keyser,Α., Wijffels,С. Acta histochem. 1968, suppl. no. 8, p. 
359. 
70 
12.European Organization for Research on Treatment of Cancer. Leu-
kaemia and Haematosarcoma Cooperative Group. Eur. J. Cancer, 
1974, 10, 413. 
IS.ClarksonjB.A. , Fried,»!. Med.Clins. N. Am. 1971, 55, 561. 
14.Killmann,S.-A. Clins. Haemat. 1973, 1, 95. 
15.Müller,D. Arzneimittelforsch. 1969, 23, 45. 
16.Killmann,S.-A. Ser. Haemat. 1968, 3, 38. 
17.Ernst,P. Scand. J. Haemat. 1973, 11, 13. 
18.Ernst,P., Faille,Α., Killmann,S.-A. ibid. 1973, 10, 209. 
19.Lampkin,В.С., McWilliams,Ν.В., Mauer,Α.M. Sem. Haemat. 1972, 
9, 211. 
71 

Chapter 5 
BONE-MARROW PROLIFERATION PATTERNS 
AND CELL KINETIC EFFECTS OF PREDNISONE 
IN ACUTE LYMPHOBLASTIC LEUKEMIA 
5.1. INTRODUCTION 
Proliferation-patterns of the bone-marrow in acute lymphoblas-
tic leukemia (A.L.L.) do not differ essentially from those in a-
cute myeloblastic leukemia (Killmann, 1968; Clarkson and Fried, 
1971) . The chance to obtain a complete remission in A.L.L. is ra-
ther high (Clarkson and Fried, 1971; Henderson, 1973). The most 
effective drug combination in A.L.L. till now,is the daily admi-
nistration of prednisone together with intermittent weekly vin-
cristine injections for at least 4 weeks. In this chapter pulse 
cytophotometric findings in A.L.L. are described before and du-
ring prednisone therapy. It became apparent that prednisone selec-
tively influences the proliferation pattern of lymphoblasts. This 
effect of prednisone offers a diagnostic aid in differentiating 
A.L.L. from other forms of acute leukemia. The observed cell kine-
tic effects of prednisone provide a possible explanation for the 
better chances to induce a complete remission in A.L.L. compared 
with therapy results in A.M.L. 
5.2. MATERIAL AND METHOD 
Patients 
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Fifteen consecutive adult patients with A.L.L. were studied. 
The cytomorphological diagnosis in all patients was confirmed at 
the World Health Organization Reference Center for Leukemias, 
Villejuif (France). Twelve of these patients were in their first 
perceptible phase at admission. Bone-marrow samples of these pa-
tients could therefore be studied before treatment, at first com-
plete remission and at the first relapse. In 3 patients observa-
tions are not available before the first remission. 
Therapy 
Most patients underwent remission inducing treatment with 
2 
courses of prednisone (40 mg/m , daily, orally) and vincristine 
2 (2 mg/m , once weekly, intravenously) for at least four weeks. 
If complete remission was not attained after three weeks dauno-
2 
mycin was added (60 mg/m , once weekly, intravenously) for at 
least two weeks. 
The first injection of vincristine was usually given at the 
fourth day after starting therapy with prednisone. In five pa-
tients the first dosage of vincristine was postponed to study 
the effects of prednisone alone during a longer period. In one 
patient the first remission was obtained with prednisone alone. 
Short term effects of prednisone on bone-marrow prolifera-
tion were also studied in seven A.M.L.-patients in various stages 
of the disease and in four patients with normal bone-marrow mor-
phology, of which three were in a complete remission of A.L.L. 
and one patient was treated for Hodgkin's disease. In these pa-
tients previous therapy was stopped at least one week before the 
administration of prednisone. 
Method 
Proliferation patterns of bone-marrow samples were determi-
ned with pulse cytophotometry according to the method described 
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in chapter 3. 
5.3. RESULTS 
5.3.1. Proliferation patterns in Acute Lymphoblastic Leukemia 
(A.L.L.) 
In general the bone-marrow of untreated A.L.L.-patients sho-
wed a low percentage of proliferating cells in S-phase and G?+M-
phase (table 5.1).In these patients the bone-marrow proliferation 
did not appear to be related to the duration of complaints before 
diagnosis, the percentage of lymphoblasts in the bone-marrow, the 
number of lymphoblasts in the peripheral blood or the hemoglobin 
values. In ten patients out of twelve a complete remission was 
achieved. In contrast to A.M.L., treated according to the L.A.M.-
2 protocol, complete remissions were also attained in patients 
with a small amount of proliferating cells. 
The percentages of S- and G2+M-phase cells in the bone-marrow sam-
ples, obtained at the first complete remission, were increased 
and almost comparable to normal bone-marrow (table 5.1).When the 
first relapse occurred the bone-marrow proliferation was decrea-
sed again. In four out of eight patients a second complete remis-
sion was achieved, independent of the proliferation patterns. 
5.3.2. Cell Kinetic effects of Prednisone 
Short-term effects of prednisone 
After three days of prednisone treatment a considerable de-
crease in S- and Gj+M-phase cells in the bone-marrow of A.L.L.-
patients was observed (figure 5.1,table 5 .11 ), while bone-marrow morpho-
logy remained almost unchanged. In most patients this effect 
was accompanied by a rapid decline of the number of lymphoblasts 
in the peripheral blood. The same dosage of prednisone did 
not change the bone-marrow proliferation of A.M.L.- patients 
and of patients with a normal bone-marrow morphology. 
(TablesS.III, 5.IV). The percentages of the S-phase cells before and 
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Table 
RESULTS OF PULSE CYTOPHOTOMETRY 
Patients 
M.B. 
M.K. 
M.E. 
J.K. 
J.H. 
P.W. 
G.G. 
E.O. 
M.H. 
G.O. 
F.P. 
T.V. 
B.D. 
M.D. 
B.A. 
Normal 
Case 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
η = 19 
Sex 
d 
d 
$ 
d 
d 
d 
d 
5 
$ 
d 
d 
d 
Î 
? 
d 
Age 
(in yrs) 
17 
15 
22 
19 
30 
21 
41 
17 
56 
17 
17 
16 
46 
19 
14 
P.C.P. befo 
treatment 
Gl 
94 
93 
93 
91 
90 
88 
84 
79 
77 
75 
66 
65 
ND 
ND 
ND 
66.3 
S 
4 
6 
6 
6 
8 
10 
12 
16 
17 
20 
27 
28 
ND 
ND 
ND 
26.1 
re 
G2+M 
2 
1 
1 
3 
2 
2 
4 
5 
6 
5 
7 
7 
ND 
ND 
ND 
7.5 
Result of 
remission 
induction 
C R . 
C R . 
C R . 
F. 
C R . 
C R . 
C R . 
C R . 
C R . 
C R . 
F. 
C R . 
C R . 
C R . 
C R . 
Percentages of G -, S- and G2+M-phases in DNA-histograms of the 
píete remission and at relapse correlated with the results of 
CR. = complete remission 
F = failure 
+ = still in remission at 1-2-75 
ND = no data available 
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IN ACUTE LYMPHOBLASTIC LEUKEMIA 
P.C.P. at time 
of complete 
remission 
S 
27 
25 
27 
ND 
27 
23 
26 
27 
26 
28 
25 
25 
26 
G 2+M 
7 
8 
9 
ND 
6 
6 
7 
7 
7 
8 
8 
8 
8 
Duration of 
1st remission 
(in months) 
11 
7 
14 
10 + 
3 + 
3 
15 
7 
19 + 
5 
26 + 
34 + 
12 
P.C.P. 
of 1st 
relapse 
S 
13 | 
5 ι 
16 
19 
14 
12 
19 
1 
19 
at time 
G 2+M 
4 
1 
4 
6 
4 
3 
3 
2 
Result of 
2nd 
remission 
induction 
F. 
C.R. 
F. 
C.R. 
C.R. 
C.R. 
F. 
F. 
Survival 
after 
relapse 
(in months) 
3 
13+ 
3 
6+ 
2 + 
8 
2 
3 
bone-marrow of A.L.L.- patients before treatment, at the first corn-
treatment. 
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Figure 5.1 
SHORT-TERM EFFECT OF PREDNISONE 
η 
\^JI 
J 
A 
S=12 
G j . M ; 4 
l fi 
i L -
в 
S.- 5 
Gî -M: 3 
- , '" 1 ' • — - — = • 1 
2n 4n — - DNA content 
DNA-histograms of the bone-marrow of a patient with A.L.L. before 
(A) and after three days of prednisone treatment (B). The thin 
line is a ten-fold magnification of the original curve. The cal-
culated percentages of cells in S- and G7+M-phase in this patient 
(G.G. in table 5.II) are shown in the right upper edge of the fi-
figures. 
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Table 5.II 
SHORT-TERM EFFECT OF PREDNISONE IN A.L.L. 
Patients 
T.V. 
B.A.* 
G.O. 
E.O. 
M.E.* 
G.G. 
M.H.* 
P.W. 
J.H. 
M.K.* 
Before treatment 
S 
27 
19 
17 
16 
16 
12 
11 
10 
8 
5 
G2+N 
6 
2 
4 
5 
4 
4 
2 
2 
2 
1 
Percentage of 
lymphoblasts 
30 
>90 
>90 
>90 
>90 
>90 
>90 
>90 
40 
70 
After 3 days 
treatment 
S 
22 
5 
9 
7 
4 
5 
7 
5 
4 
3 
G2+M 
6 
2 
3 
3 
2 
3 
2 
2 
1 
1 
of prednisone 
Percentage of 
lymphoblasts 
25 
>90 
90 
>90 
80 
>90 
>90 
>90 
40 
70 
Percentage of lymphoblasts in the bone-marrow and the percentage 
of bone-marrow cells in S- and G^+M-phase in DNA-histograms of 
A.L.L.- patients, before and after three days of treatment with 
prednisone (40mg/m /day). 
Four patients* (B.A., M.E., M.H., M.K.) were studied at relapse, 
all others at the first perceptible phase of the disease. 
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Table 5JII 
EFFECT OF PREDNISONE IN A.M.L. 
Patients 
P.B. 
J.Y. 
к.T. 
J.s. 
P.B. 
A.W. 
T.W. 
Before treatment 
S 
24 
16 
14 
11 
10 
9 
7 
G 2+M 
7 
5 
4 
2 
5 
2 
1 
Percentage of 
myeloblasts 
>90 
30 
>90 
40 
80 
>90 
>90 
After 3 days of Prednisone 
treatment 
S 
22 
16 
14 
10 
11 
11 
8 
G 2+M 
6 
4 
3 
2 
5 
2 
2 
Percentage of 
myeloblasts 
>90 
30 
>90 
40 
80 
>90 
>90 
Percentage of myeloblasts in the bone-marrow and the percentages 
of bone-marrow cells in S- and G-+M-phase in DNA-histograms of 
A.M.L.-patients, before and after three days of treatment with 
2 
prednisone (40 mg/m /day). 
Table 5.IV 
EFFECT OF PREDNISONE IN MORPHOLOGICAL NORMAL BONE-MARROW 
Patients 
T.V. 
B.A. 
M.E. 
I.S. 
Before treatment 
S 
27 
27 
26 
25 
G 2+M 
6 
8 
7 
6 
After 3 days of prednisone 
treatment 
S 
26 
26 
23 
26 
G 2+M 
6 
6 
7 
7 
Percentages of bone-marrow cells in S- and G2+M-phase in DNA-
histograms of patients with normal bone-marrow morphology, before 
2 
and after three days of treatment with prednisone (40 mg/m /day). 
Patient I.S. was treated for Hodgkin's disease, all others were 
in a complete remission of A.L.L. 
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after prednisone treatment in these three groups of patients are 
represented in figure 5.2. 
Long-term effects of prednisone 
Seven patients with A.L.L. were treated for longer periods 
with prednisone alone (table 5.V).After six to fourteen days of 
daily prednisone treatment an increase in bone-marrow cells in 
S- and Gj+M-phase was found in all these patients. In this period 
the percentage of lymphoblasts in the bone marrow deminished 
while normal hematopoietic cells reappeared. This increase in pro-
liferating cells was seen in patients with a very low percentage 
of S-phase cells before treatment as well as in patients with 
higher pretreatment values. 
5.4. DISCUSSION 
The low percentages of bone marrow cells in S- and G7+M-phase> 
found in untreated A.L.L. patients, are in agreement with former 
autoradiographic observations and determinations of the mitotic 
index (Saunders et al., 1967; Killmann, 1968). 
These values are not essentially different from the pulse cyto-
photometric results reported in A.M.L.-patients (Haanen et al., 
1974) . 
In contrast to A.M.L. treated with the L.A.M.-2 protocol, no cor-
relation was found between the bone-marrow proliferation before 
treatment and the chance to obtain a complete remission in A.L.L. 
This lack of correlation is in agreement with autoradiographic 
findings in A.L.L. (Saunders et al.,1967). The morphological nor-
mal bone-marrow at first complete remission appears to proliferate 
normally, as is also observed at first complete remission in A.M.L. 
(Büchner et al., 1972; Haanen et al., 1974). Saunders et al. (1967) 
and Clarkson (1969) reported that the proliferative activity of 
leukemic marrow was generally greater at early relapse than before 
treatment in the first perceptible phase of A.L.L. This difference 
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F i g u r e 5 . 2 
SHORT-TERM EFFECT OF PREDNISONE 
percentage S-phase 
m bone marrow 
cells 
Percentage of bone-marrow cells in the S-phase in DNA-histograms 
of patients with A.L.L., A.M.L. and with normal bone-marrow mor-
phology, determined before and after 3 days of treatment with 
2 
prednisone alone (40 mg/m / d a y ) . 
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Table 5.V 
EFFECTS OF CONTINUED ADMINISTRATION OF PREDNISONE IN A.L.L. 
Patients 
M.E. 
M.K. 
M.K.* 
G.G. 
M.B.* 
E.O. 
G.O. 
Days of pred-
nisone treatment 
0 
7 
0 
3 
6 
14 
30 
0 
3 
7 
12 
0 
3 
7 
14 
0 
7 
0 
3 
14 
0 
3 
12 
Percentage of 
lymphoblasts 
•>90 
6 
>90 
>90 
80 
50 
2 
70 
70 
70 
16 
>90 
>90 
>90 
20 
40 
10 
>90 
>90 
20 
>90 
>90 
20 
S 
6 
19 
6 
4 
9 
18 
28 
5 
3 
2 
13 
12 
I 
18 
13 
24 
16 
7 
20 
17 
9 
21 
G2 + M 
1 
4 
1 
1 
2 
6 
7 
1 
1 
1 
3 
4 
3 
1 
6 
4 
7 
5 
3 
5 
4 
3 
5 
Percentages of lymphoblasts in the bone-marrow and the percen-
tages of bone-marrow cells in S- and G2+M-phase in DNA-histo-
grams of A.L.L.-patients, before and at various days during 
2 
treatment with prednisone (40 mg/m /day) alone. The observations 
were done during the first perceptible phase of the disease or at 
relapse (pat. M.K.* and N.B.*). Patient N.K. was studied at the 
first perceptible phase (M.K.) and at relapse (M.K.*).. 
was ascribed to the lower population density of the bone-marrow 
at early relapse. In only three of our patients a higher value 
of S- and Gp+M-phase cells was found at relapse, whereas four pa­
tients showed decreased or equally low values as at pretreatment 
observations. Possibly this can be explained by less frequent con­
trols of the bone-marrow in our patients and hence a later recog­
nition of the relapse. 
Since population density increases with proceeding disease, Saun­
ders et al. (1967) suggested an inversed relation between bone-
marrow-proliferation and the duration of complaints before diag­
nosis. Such a relation was not observed in our patients. 
High dosages of prednisone in long-term administration dimi­
nish the percentage of lymphoblasts in the bone-marrow and cause 
an increase in proliferating S- and G^+M-phase cells, as demon­
strated in table 5У.These effects are propably caused by a selec­
tive lysis of lymphoblasts, independent of the cell-cycle, while 
the development of normal erythro- and myelopoiesis is not distur­
bed during prednisone treatment. This interpretation is supported 
by the rapid disappearance of mostly non-proliferating lympho­
blasts out of the peripheral blood during prednisone treatment 
(Ernst and Killmann, 1970) Besides this lytic effect prednisone 
may also have an effect on the mitotic cycle. In the first days 
of treatment the percentages of S- and G_+M-phase cells decrease, 
while the percentage of lymphoblasts is still unchanged (table 5.II). 
From combined autoradiographic and microspectrophotometric inves­
tigations Ernst and Killmann (1970, 1973) interpreted this effect 
as an inhibition of the G. to S passage of lymphoblasts. This ef­
fect was observed only in lymphoblasts as is shown in the tables 
5.II,5.III.5J.V and in figure 5.2. Similar results were obtained by 
autoradiography (Lampkin et al., 1969; Wilmans et al., 1973). The 
rapid effect of prednisone on the percentage of S-phase cells in 
the bone-marrow offers a diagnostic aid in differentiating A.L.L. 
from other forms of acute leukemia. 
Until now prednisone is the only known cytostatic with a se­
lective lytic and cell kinetic effect on blast cells without dama­
ge to the normal hematopoiesis. This may explain the good results 
84 
of this drug in remission induction of acute lymphoblastic leu-
kaemia. 
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Chapter 6 
PULSE CYTOPHOTOMETRY 
AS A MONITOR FOR TREATMENT 
IN ACUTE LEUKEMIA 
6.1. INTRODUCTION 
Several studies of cell-kinetics in acute leukemia have de-
monstrated that effectivity of cytostatic treatment is not only 
dependent on pharmacological properties of the cytostatic drugs, 
but also on the proliferative behaviour of the normal and leukemic 
cellpopulations (Clarkson et al., 1971; Clarkson and Fried, 1971; 
Killmann and Ernst, 1971, 1973; Killmann, 1974; Klein and Lennartz, 
1972; Lampkin et al., 1972; Skipper and Perry, 1970; Strijckmans, 
1971). Most antileukemic drugs have much higher efficiency 
against cells in S-, G.,- or M-phase than against cells in G. -phase 
and especially against those in the extended G.-phase. (Skipper, 
1971; Lampkin et al., 1972). In order to obtain the most effective 
use of cytostatic agents, it is necessary to measure the percenta-
ge of therapy-sensitive cells before treatment, and to study the 
effect of these drugs on the cell proliferation so that treatment 
schedules can be adapted to cell-kinetic findings. 
Basic investigations on this field were performed by autora-
diography, determinations of the mitotic index and micro-spectro-
photometry. All these techniques share the great advantage of ha-
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ving preserved the cell morphology, so that the percentages of 
the different cell cycle phases of every cell type in a cell po-
pulation can be estimated. However, these techniques are time-consu-
ming,therefore measurements can only be done in a limited number of 
patients and results can only be evaluated retrospectively. 
Pulse cytophotometry provides the possibility to determine the per-
centages of bone-marrow cells in G-, S- and G.+M- phase within 
two hours after bone-marrow sampling. As a result of this method, 
it probably will be possible to treat every individual patient ac-
cording to the cell-kinetic findings before and during the cyto-
static therapy. The main disadvantage of pulse cytophotometry is 
the loss of cell morphology, so that only the proliferation-pat-
tern of a certain cell population as a whole can be measured. How-
ever, in the first period of treatment of most acute leukemias, 
at diagnosis or at relapse, the bone-marrow is overcrowded by leu-
kemic blast cells. Especially in that stage the effects of cyto-
statics on the proliferation of an almost homogeneous blast cell 
population were investigated by pulse cytophotometry. The results 
of these studies are reported in this chapter. 
6.2. MATERIAL AND METHODS 
The cytostatic drugs under investigation were adriamycin, 
daunomycin, vincristine and cytosine-arabinoside. 
Patients 
Bone-marrow samples obtained from 39 patients were studied. 
Twenty-eight patients were treated for A.M.L., ten for A.L.L. and 
one patient for osteogenic sarcoma. Of the A.M.L.-patients 19 
were studied during the first perceptible phase, 3 at first relap-
se and 6 during both phases. Three patients were studied also du-
ring the period of their first remission of A.M.L..Of the A.L.L.-
patients 4 were studied during the first perceptible phase, 3 du-
ring first relapse and 3 during both phases. Most patients were 
treated with cytostatics before the time of investigation, but 
previous therapy was stopped at least one week before the effect 
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of a particular drug was studied. Except in the patients with A.L.L. 
in the first perceptible phase, who were continuously treated 
with prednisone. 
Methods 
Pulse cytophotometry was done on bone-marrow samples taken 
before and at several times after drug administration. 
Sampling, processing, fixation, staining and measurement of the 
bone-marrow are described in chapter 3. Of each bone-marrow 
sample smears were prepared simultaneously for morphological cell 
differentiation and for estimation of the mitotic index (M.I.). 
The M.I. was determined by counting the percentage of mitotic fi­
gures (from late prophase to late telophase) in 2000 bone-marrow 
cells. 
6.3. RESULTS 
6.3.1. Effects of Adriamycin 
Effect of adriamycin (30 mg/m2, i.v.) 24 hours after administration. 
In DNA-histograms of the bone-marrow, obtained 24 hours af-
2 ter injection of adriamycin in a dose of 30 mg/m , an increase in 
tetraploid (G2+M-phase) cells was seen in all patients. Figure 
6.1. shows an example of this accumulation of G^+M-phase cells in 
the DNA-histogram after adriamycin administration. The bone-mar­
row of this patient showed almost only lymphoblasts. Simultaneously the 
mitotic index decreased from 0.9 per cent before treatment to 0.5 
per cent 24 hours after the adriamycin injection. 
Table 6 J summarizes the percentages of bone-marrow cells in S-
and G2+M-phase, before and 24 hours after adriamycin, in 12 pa­
tients with A.M.L. and 3 patients with A.L.L. (B.A., T.V., K.M.) 
In 4 patients (J.В., M.M., H.D. and T.V.) repeated studies were 
performed during remission inducing therapy. The bone-marrow 
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Figure 6.1 
EFFECT OF ADRIAMYCIN 
R=- Ì 
^JJ ¿L 
V 
 
A 
S= 22 
Gj . M= 5 
=A 
В 
S = 21 
Gj. M= 15 
A Á 
—ι 1 ' 
2n 4n —» DNA-content 
DNA-histograms of the bone-marrow of an A.L.L.-patient before (A) 
and 24 hours after injection of 30 mg/m2 of Adriamycin (B). The 
thin line represents a magnification (2,5 x) of the original curve. 
Total number (n) of cells counted: 80.000. The calculated percen­
tages of cells in S- and G2+M-phase are shown in the right upper 
edge of the figures. 
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Table 6.1 
EFFECT OF ADRIAMYCIN IN LEUKEMIC BONE-MARROW 
Patient 
H.S. 
P.S. 
C K . 
W.Y. 
J.B. 
J.B. 
V.R. 
M.M. 
A.S. 
M.M. 
M.M. 
P.R. 
B.A. 
A.G. 
T.V. 
H.M. 
H.D. 
H.D. 
T.V. 
K.M. 
Diagnosis 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.L.L. 
A.M.L. 
A.L.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.L.L. 
A.L.L. 
Stage of 
disease 
first 
first 
first 
relapse 
first 
first 
relapse 
relapse 
first 
first 
first 
first 
relapse 
first 
relapse 
relapse 
first 
first 
relapse 
relapse 
Befo 
S 
2 
4 
5 
5 
8 
8 
8 
11 
13 
16 
17 
17 
17 
21 
22 
26 
27 
27 
27 
27 
re ADR 
G2+M 
1 
1 
1 
2 
2 
2 
2 
3 
3 
6 
6 
5 
5 
6 
5 
7 
6 
6 
6 
7 
24 hours after 
ADR 
S 
3 
4 
4 
5 
5 
6 
7 
12 
14 
16 
19 
17 
17 
23 
21 
27 
21 
28 
24 
28 
G2+M 
2 
2 
3 
3 
3 
5 
4 
11 
8 
14 
12 
9 
10 
19 
15 
12 
17 
15 
15 
12 
Percentages of bone-marrow cells in S- and Gj+M - phase in DNA-
histograms of patients with A.M.L. or A.L.L. before and 24 
2 
hours after injection of adriamycin (ADR., 30 mg/m ). 
First = during the first perceptible phase 
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smears of the samples, studied in these patients, consisted main­
ly of blast cells. The S-phase percentages remained almost con­
stant (figure 6.2) whereas the percentage of G?+M-phase cells in­
creased two to three fold after adriamycin (figure 6.3). This in­
crease in G,+M-phase cells was higher in patients with relatively 
more cells in S- and G^+M-phase before treatment. The mitotic in­
dex decreased to very low values, mostly less than 0.1 per cent. 
2 
Effect of adriamycin (30 mg/m , i.v.) at different times after 
administration. 
In 7 patients with A.M.L. and one patient with A.L.L. (pat. 
2 
T.V.) the effect of adriamycin in a dose of 30 mg/m was studied 
at different hours after injection (Table 6.II). An increase 
in Gp+M-phase cells occurred after 6 and 8 hours already, but the 
maximal increase in G2+M-phase cells was found 24 hours after 
the injection of adriamycin. Forty-eight hours after adriamycin 
the percentages of tetraploid cells were equal to the pretreat­
ment values. 
2 
Effect of adriamycin (30 mg/m , i.v.) in "normal" bone-marrow 
The effect of adriamycin on the proliferation pattern of 
morphological normal bone-marrow was investigated in 4 patients 
(tabJe6JIIl. Three patients received adriamycin for maintenance 
therapy during a complete remission of A.M.L. One patient (H.S.) 
was treated for osteogenic sarcoma. Bone-marrow samples were 
taken 18 to 24 hours after a single dosage of adriamycin. In all 
patients an increase in Gj+M-phase cells was found. 
2 
Effect of adriamycin (50 mg/m , i.v.) and of repeated dosages 
of adriamycin (2 χ 25 mg/m2, i.v.). 
The effect of one high or repeated low dosages of adriamy-
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Figure 6.2 
Percentage of bone-marrow 
cells in S-phase in DNA-his-
tograms of A.M.L. (·-·) and 
A.L.L. (o-o) patients before 
and 24 hours after injection 
2 
of Adriamycin (30 mg/m ). 
S-phase C/o) 
28 
2 4 -
20-
16-
12 
0 24 
hours after adriamycin 
F i g u r e 6 . 3 
Percentage of bone-marrow 
cells in G-+M-phase in DNA-
histograms of A.M.L. (·-·) 
and A.L.L. (o-o) patients 
before and 24 hours after 
injection of Adriamycin 
(30 mg/m 2). 
О 24 
hours after adriamycin 
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Table 6.II 
EFFECT OF ADRIAMYCIN IN LEUKEMIC BONE-MARROW AT DIFFERENT TIMES 
AFTER ADMINISTRATION 
Patient 
H.D. 
W.P. 
V.R. 
T.V. 
W.Y. 
W.Y. 
T.W. 
J.B. 
S.d.W. 
Diagnosis 
A.M.L. 
A.M.L. 
A.M.L. 
A.L.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
Stage of 
disease 
first 
first 
relapse 
relapse 
relapse 
first 
first 
first 
first 
Hours after 
adriamycin 
injection 
0 
6 
24 
0 
6 
24 
0 
6 
24 
0 
8 
18 
24 
0 
6 
24 
0 
48 
0 
48 
0 
24 
48 
0 
24 
48 
72 
Gl 
67 
66 
57 
71 
73 
68 
88 
90 
85 
67 
65 
63 
61 
93 
93 
92 
80 
82 
95 
95 
90 
89 
93 
84 
78 
85 
84 
S 
27 
26 
28 
24 
22 
22 
10 
8 
10 
27 
24 
24 
24 
5 
5 
5 
15 
13 
4 
4 
8 
6 
5 
13 
14 
11 
12 
G2+M 
6 
8 
15 
5 
5 
10 
2 
2 
5 
6 
11 
13 
15 
2 
2 
3 
5 
5 
1 
1 
2 
5 
2 
3 
8 
4 
4 
Percentages of bone-marrow cells in G.-, S- and G.+M-phase in DNA 
histograms of patients with A.M.L. or A.L.L. (pat. T.V.) at dif-
ferent hours after injection of adriamcyin (30 mg/m2) 
first= during first perceptible phase 
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Table 6.Ill 
EFFECT OF ADRIAMYCIN IN "NORMAL" BONE-MARROW 
Patient 
A.D. 
H.M. 
W.P. 
H.S. 
Hours after 
adriamycin 
0 
22 
0 
20 
0 
24 
0 
18 
24 
Gl 
67 
57 
67 
61 
70 
68 
67 
63 
63 
S 
27 
28 
26 
27 
25 
22 
27 
26 
27 
G2+M 
6 
15 
7 
12 
5 
10 
6 
11 
10 
Percentage of bone-marrow cells in G -, S- and G^+M-
phase in DNA-histograms of patients with a normal 
bone-marrow morphology before and after injection of 
2 
adriamycin (30 mg/m ). 
Patients A.D., H.M. and W.P. were in complete remission 
of A.M.L. and patient H.S. was treated for osteogenic 
sarcoma. 
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ein was investigated in 4 patients with A.M.L. (Table 6.IV) . The pa-
tients J.B.* and A.D. received a single intravenous injection of 
2 
adriamycin in a dose of 50 mg/m - A decrease in S- and Gj+M-phase 
cells was found in these patients, 24 hours after adriamycin. The 
patients P.R., W.Y. and J.B. received two lower dosages of adria-
mycin (25 mg/m2) with an interval of 24 hours. This repetition of 
a lower dosage of adriamycin caused also a decrease in the per-
centages of proliferating cells. This effect could be studied re-
peatedly in patient J.B. during different stages of the disease. 
In all patients a considerable decrease in the peripheral leuco-
cyte count was observed. The percentage of myeloblasts in the peri-
pheral blood was between 80-90 per cent in oatient J.B., A.D. and 
P.R. and 30 per cent in patient W.Y. 
6.3.2. Effect of Daunomycin 
In 4 patients with A.M.L. and 1 patient with A.L.L. (pat.M.P.) 
2 
the effect of daunomycin in a single dosage of 50 mg/m was stu-
died (Table 6.V) .The bone-marrow samples of these patients showed 
90-100 per cent of blast cells at the time of the investigation. 
In all patients but one (V.R.) an increase in G2+M-phase cells 
was found 24 hours after the injection of daunomycin, while the 
mitotic-index stayed rather low. 
The percentages of S-phase cells after this dosage of daunomycin 
were almost equal to the pretreatment values. 
6.3.3. Effect of Vincristine 
The effect of vincristine was investigated in 7 patients with 
A.L.L. and 3 patients with A.M.L. (Table 6.VI) .The bone-marrow of 
all patients but one showed a high percentage of blast cells. In 
patient G.O. only 20 per cent of lymphoblasts was found. An in-
crease in G2+M-phase cells was observed in all patients 6-72 hours 
after the intravenous injection of vincristine in a dose of 2 mg/m . 
In two patients (G.G. and B.A.) bone-marrow was taken 6 hours 
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Table 6. IV 
EFFECTS OF DIFFERENT DOSAGES OF ADRIAMYCIN 
Patients 
J.В.* 
A.D. 
P.R. 
W.Y. 
J.B. 
J.B. 
Diagnosis 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
A.M.L. 
Stage of 
disease 
first 
relapse 
first 
first 
relapse 
relapse 
Hours after 
first injection 
of adriamycin 
0 
24 
0 
24 
о 
48 
0 
48 
0 
48 
0 
48 
Gl 
88 
94 
79 
83 
79 
91 
76 
82 
70 
84 
73 
82 
S 
10 
4 
17 
15 
15 
5 
18 
13 
24 
12 
23 
15 
G 2+M 
2 
2 
4 
2 
6 
4 
6 
5 
6 
4 
4 
3 
Number of 
peripheral 
leuc.xlO Д 
9.0 
0.7 
105.0 
55.0 
72.0 
6.4 
2.4 
0.6 
19.2 
2.4 
24.0 
5.3 
Percentages of bone-marrow cells in G -, S- and G^+M-phase in 
DNA-histograms and the number of leucocytes in the blood of pa­
tients with A.M.L. before and 24 hours after a single dosage of 
adriamycin (50 mg/m2, in patient J.B.* and A.D.) or after repeated 
2 dosages (25 mg/m at 0 and after 24 hours) of adriamycin. 
Patient J.B. was studied repeatedly. 
First= during the first perceptible phase. 
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Table б. 
EFFECT OF DAUNOMYCIN 
Patients 
G.К. 
V.R. 
M.P. 
M.M. 
G.B. 
Diagnosis 
A.M.L . 
A.M.L. 
A.L.L. 
A.M.L. 
A.M.L. 
Stage of 
disease 
first 
first 
relapse 
first 
first 
Hours after 
daunomycin 
injection 
0 
24 
0 
24 
0 
24 
0 
24 
0 
24 
Gl 
93 
92 
92 
90 
85 
77 
76 
69 
73 
58 
S 
5 
5 
6 
8 
12 
11 
18 
20 
21 
23 
G2+M 
2 
3 
2 
2 
3 
12 
6 
11 
6 
19 
M.I. 
0.10 
o.io 
0.18 
0.25 
0.44 
Percentages of bone-marrow cells in G.-, S- and G2+M-phase in 
DNA-histograms and the mitotic index (M.I.) in the bone-marrow 
of patients with A.M.L. or A.L.L. before and 24 hours after in-
2 jection of daunomycin (50 mg/m ). 
First= during the first perceptible phase 
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Table 6.VI 
EFFECT OF VINCRISTINE 
Patients 
G.О. 
F.P. 
E.О. 
M.B. 
G.G. 
В.Α. 
G.О. 
G.B. 
J.B. 
J.S. 
Diagnosis 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
A.M.L. 
A.M.L. 
A.M.L. 
Stage of 
disease 
first 
first 
relapse 
relapse 
second 
relapse 
relapse 
first 
relapse 
relapse 
relapse 
Hours after 
vincristine 
injection 
0 
24 
0 
24 
0 
24 
72 
0 
24 
0 
6 
20 
40 
0 
6 
24 
0 
18 
24 
0 
18 
0 
24 
0 
8 
Gl 
88 
82 
86 
83 
82 
78 
85 
76 
62 
80 
60 
63 
75 
77 
66 
73 
76 
69 
71 
90 
86 
84 
77 
83 
79 
S 
9 
11 
11 
9 
14 
12 
12 
17 
19 
17 
18 
19 
16 
20 
17 
15 
21 
21 
21 
8 
8 
13 
14 
14 
15 
G 2+M 
3 
7 
3 
8 
4 
10 
3 
7 
19 
3 
22 
18 
9 
3 
17 
12 
3 
10 
8 
2 
6 
3 
9 
3 
6 
M.I. 
0.5 
4.0 
0.7 
4.8 
0.6 
5.1 
1.2 
10.1 
14.0 
10.3 
0.4 
12.0 
8.1 
0.8 
4.7 
0.2 
3.1 
0.4 
5.0 
0.5 
3.0 
Percentages of bone-marrow cells in G.-, S- and G2+M-phase in 
DNA-histograms and the mitotic index (M.I.) of the bone-marrow 
of patients with A.L.L. or A.M.L at different hours after injec-
2 
tion of vincristine (2 mg/m ) . First= during the first perceptible 
Table 6.VII 
COMBINED EFFECT OF ADRIAMYCIN AND VINCRISTINE 
Patients 
M.P. 
G.BE. 
B.A. 
G.G. 
Diagnosis 
A.L.L. 
A.L.L. 
A.L.L. 
A.L.L. 
Stage of 
disease 
relapse 
first 
relapse 
relapse 
After injection 
of ADR and VCR 
0 
24 
0 
30 
0 
24 
0 
30 
Gl 
85 
77 
84 
78 
78 
72 
75 
71 
S 
12 
12 
13 
14 
17 
17 
19 
18 
G2+M 
3 
11 
3 
8 
5 
11 
6 
11 
M.I. 
0.4 
0.2 
0.5 
0.5 
0.3 
0.2 
0.2 
0.6 
Percentages of bone-marrow cells in G.-, S- and G2+M-phase in DNA-
histograms ,and the mitotic index of the bone-marrow of patients 
with A.L.L-, before and 24 or 30 hours after injection of adriamy-
2 2 
ein (30 mg/m ) and vincristine (2 mg/m ). 
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after injection. The increase in G2+M- phase cells appeared to be 
higher than at 20-24 hours after vincristine. Simultaneously a 
pronounced increase of the mitotic index appeared. The S-phase 
compartment showed no or only slight changes during observation. 
6.3.4. Effect of simultaneous administration of Adriamycin and 
Vincristine 
In 4 patients with A.L.L. the effect of simultaneous injec-
tions of adriamycin (30 mg/m2) and vincristine (2 mg/m2) was stu-
died (Table 6.VII).In all patients an increase in G^+M-phase cells 
was seen in the samples obtained 24 or 30 hours after drug admi-
nistration, but the mitotic index remained in the same range as 
before treatment. The rise of Gj+M-phase cells was not higher 
than could be expected after injection of a single drug. 
6.3.5 . Effects of Cytosine-Arabinoside (ARA-C) 
Short-term effects of ARA-C 
Short-term effects of ARA-C were studied in 5 patients with 
A.M.L. during the first course of treatment (Table 6.VIII). in 3 
patients a decrease in S- and G2+M-phase cells was found in the 
bone-marrow samples 8 hours after a single injection of ARA-C 
2 
(100 mg/m ). In the samples, taken 24 hours after the injection 
the same proliferation pattern was found as before treatment. 
Long-term effects of ARA-C 
Effects of repeated injections of ARA-C were studied in 10 
patients with A.M.L. (table 6.IX). Six patients (G.K., S.E., V.Du., 
B.M., M.M. and V.L.) were treated with ARA-C, administered every 
12 hours as a "push" injection of 100 mg/m2 according to the 
L.A.M.-2 protocol*of the E.O.R.T.C. In these patients bone-mar-
row samples were taken at day 4 and 8 of the ARA-C course,12 
hours after the previous injection. Four patients (T.W., P.C., 
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Table 6.Vili 
SHORT-TERM EFFECT OF CYTOSINE-ARABINOSIDE (ARA-C) 
Patient 
H.R. 
K.J. 
V.B. 
G.K. 
J.S. 
Hours after 
ARA-C injec-
tion 
0 
8 
0 
8 
0 
8 
24 
0 
24 
0 
24 
% Myeloblasts 
50 
50 
90 
90 
>90 
>90 
>90 
>90 
>90 
50 
50 
Gl 
91 
94 
83 
94 
85 
95 
86 
89 
88 
86 
85 
S 
7 
5 
13 
4 
12 
4 
11 
9 
10 
12 
12 
G 2 + M 
2 
1 
4 
1 
3 
1 
3 
2 
2 
2 
3 
Percentages of bone-marrow cells in G.-, S- and G^+M-phase in 
DNA-histograms and the percentages of myeloblasts in the bone-mar-
row of patients with A.M.L., before and at different hours after 
injection of ARA-C (100 mg/m ) during the first treatment-course. 
104 
figure 6.IX 
LONG-TERM EFFECTS OF ARA-C 
Patients 
G.K. 
S.E. 
V.Du. 
B.M. 
M.M. 
V.L. 
T.W. 
P.C. 
v.s. 
v.s. 
F.L. 
Time studied 
first course 
of treatment 
II 
II 
II 
II 
II 
и 
first relapse 
first course 
of treatment 
second course 
of treatment 
first course 
of treatment 
Days of 
ARA-C 
treatment 
0 
8 
0 
4 
0 
4 
8 
0 
4 
8 
0 
8 
0 
4 
0 
4 C 
0 
4 C 
0 
4 C 
0 
4 C 
0 
4 C 
% Myeloblasts 
> 90 
> 90 
> 90 
> 90 
> 90 
> 90 
> 90 
> 90 
> 90 
> 90 
60 
50 
75 
70 
> 90 
> 90 
65 
60 
>90 
> 90 
50 
40 
>90 
>90 
Gl 
95 
90 
95 
86 
93 
89 
84 
93 
83 
81 
79 
70 
80 
67 
95 
92 
86 
86 
86 
90 
84 
85 
84 
86 
S 
4 
6 
4 
12 
6 
9 
13 
6 
13 
15 
16 
24 
16 
27 
4 
7 
10 
12 
11 
9 
13 
13 
13 
13 
1 
G 2+M 
1 
2 
1 
2 
1 
2 
3 
1 
4 
4 
5 
6 
4 
6 
1 
1 
4 
2 
3 
1 
3 
2 
3 
1 
Percentages of bone-marrow cells in G-, S- and G^+M-phases in DNA-
histograms and the percentages of myeloblasts m the bone-marrow 
of patients with A.M.L., before and at day 4 or 8 of ARA-C treat­
ment. The patients above the line were treated with two daily "push" 
2 injections (100 mg/m ). Four patients (below the line) were treated 
2 с 
with continuous infusions of ARA-C (24 0 mg/m /day). 4 = four days 
of continuous infusion. 
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V.S. and F.L.) were treated with continuous infusions of ARA-C 
2 
during five days in a dose of 240 mg/m /day, according to the 
L.A.M.-3 protocol of the E.O.R.T.C. In these patients a bone-mar­
row puncture was done on day 4 during ARA-C infusion. 
After 4 or θ days of intermittent ARA-C therapy an increase in S-
and Gj+M-phase cells was found in the bone-marrow. However,after 
4 days of continuous ARA-C infusion the percentage of S-phase 
cells was not higher than before treatment and the percentage of 
Gp+M-phase cells after continuous therapy was generally lower 
than before treatment, 
6.4. DISCUSSION 
As shown in table 6.1and 6.11 and in figure 6.3. , a single rela­
tive low dosage of adriamycin causes an increase in the percenta­
ge of tetraploid cells in leukemic bone-marrow. This increase must 
be due to an accumulation of cells in the G2-phase, because a 
drop in the mitotic index is seen at the same time and the percen­
tage of S-phase cells is unchanged. An increasing accumulation of 
cells in the Gj-phase was observed between б and 24 hours after 
the injection of adriamycin. This time-interval indicates that 
cells which were in the S-phase before treatment are blocked in 
the G^-phase by adriamycin. 
The observation that the Gj-blocklng effect was more pronounced 
in patients with a high percentage of S-phase cells before treat­
ment is a further argument for the hypothesis that especially cells in 
S-phase before treatment are blocked in the Gj-phase by adriamy­
cin (Table 6,11, figure 6.3). 
Blocking of cells in G2 by adriamycin was reported by Wheatly 
(1972) for HELA-cells,and by Göhde (1973) for Ehrlich ascites 
tumor cells. 
Very similar effects in human acute leukemia were reported by 
Ernst (1973a) and Strijckmans et al. (1973) for daunomycin. This 
is consistent with our observations after daunomycin, as listed 
in table 6.V. Since daunomycin and adriamycin (14-hydroxy-dauno-
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mycin) have most of the biochemical properties in common, a simi-
larity in kinetic effects may be expected. 
From a therapeutic point of view the increase in' the total a-
mount of S- and G9+M-phase cells, 24 hours after a low dosage of 
adriamycin or daunomycin may be of interest. Cells in these cell 
cycle phases are most sensitive to cytostatic drugs, therefore admi-
nistration of cell cycle dependent cytostatics may be more effec-
tive 24 hours after the injection of adriamycin or daunomycin. 
However the G2-blocking effect of adriamycin seems not to be re-
stricted to leukemic blast cells, as is shown in table 6.III.Dif-
ferences in cell kinetic effects between blast cells and normal 
bone-marrow cells might be usefull for a more selective therapy. 
Unfortunately such differences were not observed after adriamycin 
administration. In some patients Ernst (19 73a) and Strijckmans et 
al. (1973) observed a decrease in the labeling index of the leu-
kemic blast cells after daunomycin. In our patients the S-phase 
percentages were generally unaffected by daunomycin and the lower 
dosage of adriamycin. But the effects on S-phase cells might be 
dose dependent, as stated by Strijckmans et al. (1973) for dauno-
mycin. 
Actually in our patients a dose-dependency was found for 
adriamycin.Injections of higher dosages or repeated dosages of 
adriamycin cause a decline in the percentages of S-phase cells in 
all patients as is shown in table 6.IV.Probably at higher dosages 
more adriamycin molecules have intercaUated in the DNA-structure, 
resulting in a decrease in DNA-synthesis. Besides this kinetic ef-
fect, a rapid fall of the peripheral leucocyte count is observed, 
possibly due to an effect of adriamycin independent of the cell 
cycle. 
Similar observations were reported by Ernst (1973a)and Strijck-
mans et al. (1973) after daunomycin treatment in acute leukemia. 
Blocking and killing effects of adriamycin probably represent sta-
ges in a spectrum of cell cycle disturbances, dependent of dosage 
and sensitivity of the cells. 
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Vincristine causes an increase in G2+M-phase cells 6-24 hours 
after drug administration, as demonstrated in table 6.VI. This 
increase in G2+M-phase cells was accompanied by a comparable rise 
of the mitotic index. The S-phase compartment remained unchanged 
during the observation period. After vincristine administration 
cells were probably blocked in the M-phase. These findings are in 
agreement with the studies of Lampkin et al. (1969, 1972) and 
Ernst (1973b) who demonstrated by other techniques that leukemic 
cells are blocked in the metaphase by vincristine for a period 
of 1-28 hours after drug administration. Klein and Lennartz (1974) 
observed a partial synchronization of tumor cells after vincris-
tine. The period of observation in our patients was too short to 
follow the subsequent fate of the cells which were accumulated in 
the M-phase by vincristine. 
Simultaneous injection of adriamycin and vincristine resulted in 
a G^-block, which is demonstrated in tableô.VIIby the increase in 
Gp+M-phase cells and the unchanged mitotic index at the same time. 
From a cellkinetic point of view it is probably not logical to admi-
nister these drugs at the same time. The G^-block induced by adri-
amycin will prevent cells to attain mitosis where they would be 
stopped by vincristine. The effect of this combination is not 
better than the effect of adriamycin alone, rather toxicity is 
increased. 
From these data it can be concluded that if vincristine and 
adriamycin or daunomycin should be given as combined therapy it 
is better to inject vincristine some hours before or at least 
24-hours after adriamycin or daunomycin. 
Cytosine-arabinoside causes a decrease in S- and Gj+M-phase 
cells in myeloblastic bone-marrow 8 hours after administration 
(table б ІІІ). 24 Hours after ARA-C injection S- and Gj+M-phase 
percentages are recovered to pretreatment levels. The small num­
ber of these observations allows no extensive interpretation. How­
ever the short-term effects of ARA-C were extensively studied by 
Lampkin et al. (1971, 1972) and Ernst et al. (1973c), who showed 
that ARA-C acts as a pure S-phase inhibitor in the first hours af-
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ter injection already. A recovery of S-phase cells and mitotic 
index, which could be interpreted as cell recruitment, was seen 
24 hours after drug administration. Our results are consistent 
with these observations. 
Lampkin et al. (1971, 1972) reported an increase of S-phase 
cells determined by autoradiography 24-72 hours after ARA-C in-
jections and after intermittent ARA-C treatment. Pulse cytophoto-
metric findings revealed also an increase in S- and G_+M-phase 
cells after intermittent ARA-C treatment (table 6. IX) . 
However after continuous ARA-C infusions with a comparable dosa-
ge of the drug such an increase was not observed. This differen-
ce between intermittent and continuous ARA-C treatment is possi-
bly one of the explanations for the rather disappointing results 
in patients treated according to the L.A.M.-3 protocol.(Prelimi-
nary Report Leukemia and Hematosarcoma Cooperative Group EORTC. 
Feb. 75). Chemotherapy which increases S-phase cells offers the 
possibility to subsequent administration of specific S-phase in-
hibitors to potentiate cytoreductive effects. Therefore intermit-
tent therapy with ARA-C should possibly be preferred to conti-
nuous infusion. 
However, an increase in S-phase cells in the DNA-histograms 
after ARA-C therapy could also be caused by an increase in so-
called "U"-cells, i.e. cells which do not incorporate H-
TDR but still have a DNA-content of S-phase cells (Ernst, 1973d) 
The number and the nature of these cells in leukemia are still 
unknown. An asynchronous disturbed DNA synthesis or enzyme dis-
turbances, by which these cells can not incorporate exogenous thy-
midine, may be possible explanations for this phenomenon (Ernst 
et al., 1973). The possibility of an increase in "U" cells can not be 
ruled out in our patients, since no autoradiography was done. How-
ever if a large fraction of the cells with a DNA-content of S-
phase cells should have been "U" cells the observed increase in 
G-p+M-phase cells would not have occurred. 
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Chapter 7 
GENERAL DISCUSSION 
Although cytostatic treatment of acute leukemia is unsatis-
factory, it is still the only therapeutic approach which can pro-
duce a temporary remission of the disease. In some patients with 
acute leukemia this type of therapy results in a long survival or 
perhaps even in a cure (Burchenal,1970). Most of the presently 
used cytostatic treatment schedules for acute leukemia are based 
on empirical findings in clinical trials. 
The development of more rational chemotherapeutic programs, 
based on fundamental knowledge of the effects of drugs in normal 
and leukemic cells, will probably improve the results of therapy. 
Such approach requires information about several factors like 
drug transport into the cells, drug metabolism, interaction of 
drugs and about cell proliferation patterns before and during the-
rapy (chapter 1.7.) 
Some aspects of the relation between the clinical results of 
chemotherapy and the bone-marrow cell proliferation, investigated 
by means of pulse cytophotometry, are presented in this study. 
The main advantage of this method is the fact that prolifera-
tive data of a given bone-marrow sample can be obtained within two 
hours after aspiration. This provides the possibility to obtain 
cell kinetic data before and during the cytostatic treatment, and 
to adapt to these findings the treatment of individual patients. 
Similar methods like autoradiography and micro-cytophotometry are 
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time-consuming and laborious and therefore inappropriate for 
routine measurements. Pulse cytophotometry moreover, allows for 
a high statistical reliability by the measurement of approxima-
tely 10 cells in each sample. 
One disadvantage of pulse cytophotometry is that the informa-
tion obtained is limited to the percentage of cells of a given 
cell population in the G-, S- and G^+M-phase. The same holds for 
micro-cytophotometry, whereas autoradiography reveals only infor-
mation about the S-phase. Data of generation times of bone-marrow 
cells still have to be obtained by other methods (chapter 1.3.) . 
The main disadvantage of pulse cytophotometry however is the 
measurement of the proliferation-pattern of a mixed cell popula-
tion, irrespective to the different cell types present. This allows 
therefore only very limited interpretation of results obtained in 
bone-marrow samples containing different cell types. In acute 
leukemia this objection is obviated by the almost homogeneous 
blast cell population in the full blown phase of the disease. 
In this stage pulse cytophotometry gives reliable information 
about the proliferation of the abnormal cells. However as soon 
as cell differentiation reappears the pulse cytophotometnc re-
sults are no longer representative for the leukemic cell-popula-
tion studied, and changes in histograms at this stage reflect 
rather cell composition than differences in cell-proliferation. 
In spite of these limitations pulse cytophotometry can provide 
important information about the relationship between cell-proli-
feration and cytostatic therapy in patients with acute leuke-
mia, as demonstrated by some of the findings in this study. 
The observed relation between the cell proliferation-pattern 
and the chance to obtain a complete remission in A.M.L. may have 
important practical consequences for the treatment (chapter 4). 
It should be noted, however, that this correlation between pro-
liferation and therapy-response is found in a group of patients 
treated with a particular protocol. Patients with a low percen-
tage of S- and G^+M-phase cells might have a better chance to 
attain a complete remission with a different therapeutic program. 
Whether the same relation between proliferation and therapy-result 
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exists in other treatment schedules is under investigation. 
A similar positive correlation between the labeling index of 
the bone-marrow before treatment and the response-rate of diffe-
rent cytostatic treatment programs is reported by several authors 
(Burke and Owens, 1971; Huber et al., 1971; Gross et al., 1973; 
Vogler et al., 1974). Scarfe et al. (1974) however, found no cor-
relation between the pretreatment labeling index and response to 
treatment with cytosine-arabinoside and daunomycin in A.M.L. 
In a certain percentage of patients with acute leukemia, the 
blast cells are undifferentiated which makes distinction between 
lymphoid and myeloid origin almost impossible. In this group of 
patients the selective short-term effect of prednisone, measured 
with pulse cytophotometry, can add a functional criterion for the 
choice of therapy (chapter 5.3.2.). 
The application of pulse cytophotometry in the investigation 
of the effects of cytostatics on bone-marrow cell proliferation 
provides information which can be used for an optimal choice of 
drug-combinations, application-manners and time-scheduling of 
drugs. Pulse cytophotometric findings in patients,treated accor-
ding to L.A.M.-3 protocol,were different from those treated accor-
ding to L.A.M.-2. The L.A.M.-2 protocol consisted of intermittent 
injections of Ara-C whereas in L.A.M.-3 Ara-C was given in conti-
nuous infusion. 
Four to eight days after intermittent Ara-C treatment a gra-
dual increase in S- and G^+M-phase cells was observed. This ef-
fect was not observed after four days of continuous treatment, 
where no influence on proliferation pattern occurred. These ob-
servations are consistent with the disappointing clinical results 
of the L.A.M.-3 protocol (chapter 6.3.5.) 
The observations after separate or combined administration 
of adriamycin and vincristine once more demonstrate the ability 
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of pulse cytophotometry to examine cell-kinetic effects of cyto-
static drugs. The value of these observations would greatly in-
crease if the effects of cytostatics on the proliferation of nor-
mal hematopoietic cells and especially stem cells could be measured. 
Combination of pulse cytophotometry with appropriate cell-separa-
tion procedures will provide possibilities to distinguish between 
the effect of chemotherapeutic drugs on leukemic and normal hema-
topoietic cells. These informations could be exploited for a se-
lective eradication of the leukemic cell population. The advan-
tages of a selective chemotherapeutic effect on leukemic cells are 
demonstrated by the action of prednisone in acute lymphoblastic 
leukemia as described in chapter 5. 
The preliminary observations with pulse cytophotometry in 
acute leukemia indicate that this method can provide valuable 
informations on some aspects of the cell proliferation. Further 
experiences with pulse cytophotometry, improvement of cell-pro-
cessing and development of cell-separation methods,may contri-
bute to a rational selection of optimal cytostatic treatment sche-
dules in acute leukemia. 
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SUMMARY 
Some aspects of the relationship between bone-marrow cell 
proliferation and chemotherapy in acute leukemia were investiga-
ted by means of pulse cytophotometry. 
Bone-marrow cell proliferation in acute leukemia is charac-
terized by a low proliferative activity of the leukemic cell po-
pulation. This feature forms a main obstacle for cytostatic treat-
ment, because most of the presently used cytostatics are only ef-
fective on proliferating cells. Therefore informations about the 
cell proliferation are relevant for the effectivity of cytostatic 
treatment. 
The proliferation pattern of normal and leukemic bone-marrow 
samples was studied by measuring the DNA-content of large num-
bers of cells by pulse cytophotometry. The principles of this 
method and the main technical data of the measuring system, the 
pulse cytophotometer, are described in chapter 2. Investigations 
concerning the preparation and staining of bone-marrow cells for 
pulse cytophotometry are discussed in chapter 3. As a result of 
these investigations a method for cell-processing and staining, 
slightly different from those mentioned in the literature, is des-
cribed. The percentages of S-phase cells determined by autoradio-
graphy and pulse cytophotometry correlate well, both in normal 
and in leukemic bone-marrow. 
In normal bone-marrow samples an average of 66.3%of the bone-
marrow cells is found in the G.-phase, 26.]% in the S-phase and 7.5% 
in the G2+M-phase. 
In acute leukemia a lower percentage of cells is found in 
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the S-phase and in the G2+M-phase of the cell cycle, correspon-
ding to a smaller "proliferating pool". At remission in acute leu-
kemia the proliferation-pattern is restored to normal. 
The chance to obtain a complete remission with a particular 
therapy in the first perceptible phase of acute myeloblastic leu-
mia (A.M.L.) appeared to correlate with the percentage of S-phase 
cells present before treatment (chapter 4). 
In acute lymphoblastic leukemia (A.L.L.) the cell-prolifera-
tion of the lymphoblasts is selectively influenced by prednisone 
(chapter 5). This effect of prednisone explains possibly the bet-
ter chances to obtain a complete remission in A.L.L., compared to 
A.M.L. The selectivity of the prednisone-effect, measured by 
pulse cytophotometry, offers a diagnostic aid in differentiating 
A.L.L. from other forms of acute leukemia. 
By means of pulse cytophotometry the various effects of some 
cytostatic drugs on the cell cycle are studied. It is demonstra-
ted that Adriamycin causes,approximately 24 hours after administra-
tion/an increase in G2-phase cells in bone-marrow of patients 
with A.M.L. and A.L.L. as well as in four patients with a 
normal bone-marrow morphology. Similar effects are observed af-
ter Daunomycin administration. Six to twenty-four hours after 
Vincristine administration an increase of cells in the M-phase is 
observed in patients with A.M.L and A.L.L. Cytosine-arabinoside 
(ARA-C) causes a rapid decrease in S-phase and Gp+M-phase cells 
in patients with A.M.L. 
Four or eight days after intermittent Ara-C treatment a gra-
dual increase in S- and G2+M-phase cells is seen, probably caused 
by cell-recruitment. This effect is not observed after four days 
of continuous Ara-C treatment with a same dosage. Cell-kinetic 
data, obtained with pulse cytophotometry may contribute to a more 
effective cytostatic treatment and by this improve the ultimate 
prognosis of acute leukemia. 
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APPENDIX 
Chemotherapy for remission induction in acute myeloblastic leuke-
mia. 
L.A.M. 2 protocol 
Randomization of patients in three treatment groups: 
I. Cytosine-Arabinoside (ARA-C) alone 
2 
ARA-C 100 mg/m I.V. (push injection) every 12 hours for 7-
10 days. Rest period: 2 or 3 weeks. A total of 3 courses of 
treatment is given. 
II ARA-C and Thioguanine (6 TG) 
ARA-C as in I 
6 TG 80 mg/m P.O. every 12 hours for 7-10 days. First dose 
given 6 hours before ARA-C in 3 courses of treatment 
H I ARA-C and Daunomycin (DRB) 
ARA-C a s i n I 
DRB 60 mg/m2 I.V. (push injection) 12 hours before the first 
ARA-C dosage in 3 courses of treatment 
Results of remission induction are evaluated after three courses 
of treatment. Complete remission is said to be present if the pa-
tient is clinically free from disease, if he has a normal peri-
pheral blood, and if a double blind examination at the WHO Refe-
rence Center for Leukemias and Hematosarcomas (Villejuif) reveals 
less than 5% of leukemic cells in a bone-marrow of normal cellula-
rity. 
L.A.M. 3 protocol 
Randomization in four treatment groups 
I Vincristine (VCR) and ARA-C 
2 
Vincristine 1 mg/m I.V. (push injection) at day 1 and 2. 
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ARA-C 240 mg/m I.V. infusion for 12 hours at day 3-7. The first 
infusion is given 12 hours after VCR, the interval between the 
infusions is 12 hours. At least 2 courses of treatment are given 
with a rest period of 10-14 days. 
II ARA-C and VCR 
ARA-C 240 mg/m2 I.V. infusion for 12 hours at day 1-5. 
VCR 1 mg/m2 I.V. (push injection) at day 6 and 7. At least 2 
courses of treatment are given, with an interval of 10-14 days. 
ΠΙ ARA-C intermittent infusions 
2 
ARA-C 240 mg/m I.V. infusion during 12 hours for 5 days. At 
least 2 courses of treatment are given with an interval of 
12-16 days. 
IV ARA-C continuous infusions 
2 
ARA-C 240 mg/m I.V. continuous infusions during 24 hours for 
5 days. At least 2 courses of treatment are given with an inter­
val of 12-16 days. 
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STELLINGEN 
1 
Het proliferatiepatroon van het beenmerg bepaald met behulp van 
puls cytophotometrie kan bij de behandeling van patiënten met 
akute leukemie een leidraad гізп voor de keuze van chemotherapeu-
tica en het tijdstip van toediening. 
2 
Patienten met een ongedifferentieerde akute leukemie, waarbij het 
percentage van de beenmergcellen m de DNA-synthese fase daalt na 
toediening van prednison gedurende drie dagen, dienen te worden 
behandeld als een akute lymfoblasten leukemie. 
3 
Voor de remissie induktie bij volwassenen met akute lymfoblasten 
leukemie verdient de kombinatie prednison-vincnstine de voor­
keur. 
Willemze,R. , H.Hillen, С.A.Hartgrink-Groeneve ld, C.Haanen 
(1975) Treatment of acute lymphoblastic leukemia in adults, 
a retrospective study of 41 patients (1970-1973) . Blood, in 
pres s. 
4 
Palliatieve therapie van akute myeloblasten leukemie bij patiënten 
ouder dan 50 ]aar is zinvoller dan cytostatische therapie die ge-
richt is op het verkrijgen van een complete remissie. 
Crosby,W.H. (1974) Grounds for optimism in treating acute 
granulocytic leukemia. Arch Int. Med. 134, 177. 
5 
De haaruitval ten gevolge van intraveneus toegediende cytostatica 
vermindert aanzienlijk door enkele minuten vóór tot 20 minuten na 
de injectie een stuwband aan te brengen ter hoogte van de schedel-
basis . 
6 
Het is onvoldoende bekend dat bij de differentiële diagnostiek van 
de ziekte van Cushing chronisch alcohol misbruik overwogen moet 
worden. 
Dillon,R.S. (1973) Handbook of Endocrinology, Lea and Febi-
ger, Philadelphia, p. 495. 
7 
Het verdient aanbeveling om bij de beoordeling van de aktiviteit 
van de ziekte van Hodgkin naast de bezinking en het fibnnogeen 
gehalte van het plasma ook het complement gehalte van het serum 
te betrekken. 
8 
De toeneming van de erythropoiese, door sommige auteurs waargeno-
men, tijdens de behandeling van dialyse-patiënten met hoge dose-
ringen anabole Steroiden wordt niet veroorzaakt door een stijging 
van het erythropoietine gehalte in het serum. 
9 
De unieke organisatie van de Nederlandse Trombosediensten biedt de 
mogelijkheid om binnen enkele jaren aan te tonen of trombocyten-
funktie-remmers een betere bescherming bieden tegen artenële vaat-
occlusies dan de nu omstreden therapie met coumanne derivaten. 
10 
De technische ontwikkelingen op het 
tiek maken de zogenaamde röntgen-aa 
ongewenst als het toekennen van het 
springers. 
gebied van de röntgen-diagnos-
tekening voor internisten even 
vliegbrevet aan polsstok-hoog-
H.F.P.Hillen Nijmegen, 14 juni 1975 


